Future Thinking: MIT Solve & FPC Workshop Strategy

*|MC:SUBJECT|*
November 2022    |    Did someone forward you this email? Subscribe Here
Future Planet & MIT Solve Alliance
The Workshop Strategy and the Wei Foward Report II
At the end of September, on the eve of the General Assembly annual gathering in New York, it was exciting to be able to join forces with our Ally, MIT Solve - and to announce our intention to launch the Workshop Strategy. The initiative aims to invest for-profit capital in Solver Teams emerging from Solve’s Global Challenges.

The event, held at the Penn Club in New York, focused on how universities, entrepreneurs and investors can align impact and profit to accelerate change. Born out of the MIT President’s Office in 2015, Solve acts as a global hub to convene innovators to one of the world’s most enterprising universities. Many of these companies would not ordinarily be reached by investors. This includes Ventures from the global South - widening access for entrepreneurs but also enabling FPC to tap into the highly filtered deal flow from fast-growing markets.

The Queen of Raw, one of the exemplars of what is possible as an alumna of MIT Solve, gave a stirring presentation. Their solution to help our planet by reducing waste using revolutionary software is now widely used across the fashion industry, including by large corporates. Queen of Raw's charismatic founder, Stephanie Benedetto, recounted her moving origin story - her father as a recently arrived immigrant to Manhattan nearly a hundred years ago built up a business from nothing but upcycled discarded items of clothing. Stephanie's team, inspired by this approach, have developed sophisticated technology to identify and eliminate waste in textile and other supply chains. A recent example of success saved billions of tons of water around the world, water that will instead be available for citizens to drink and utilise for daily living and survival, instead of becoming polluted and unusable.

Accompanied by the FPC Team, Advisory Board Member Lord Wei spoke during the event and built on these presentations by giving a stirring tribute to the late Queen Elizabeth. Queen Elizabeth was much loved by the people of New York City as well as across America and the world. Lord Wei highlighted how we can all be inspired by her sense of duty and care for people, as well as the importance of global reconciliation. He invited participants in and beyond the room to contribute to the forthcoming second edition of the Wei Forward report. The new edition seeks to explore how the financial ecosystem for impactful ventures can be further encouraged, understand its evolution around the world, and consider how more investment can be directed to helping those on lower incomes lead better lives with a lower cost of living and more reliable, renewable, and secure energy.

With existing FPC portfolio companies such as Tokamak Energy, Solasta Bio and Vaccitech (to name but a few) - and many of the hundreds of companies who have gone through the MIT Solve process - there is great opportunity to deliver sustainable returns for investors while helping to build much-needed resilience and tackle poverty affecting peoples all across the world.
 
Thank you to everyone who joined Future Planet Capital, Lord Wei, Stephanie Benedetto, and Alex Amouyel, for the launch of our alliance with MIT Solve and the announcement of the upcoming Workshop Strategy at the Penn Club in New York City.

We hope that you found the conversation as fruitful as we did, and thank you to those who actively contributed to those discussions. 

If you are interested in learning more about our alliance with MIT Solve and the Workshop Strategy please do not hesitate to get in touch with Ed Phillips

Over the next three months, we will also be hosting another two roundtable events in Singapore and London as part of the upcoming second installment of the "Wei Forward" Report by Lord Wei. We welcome you to join us at these events to take the conversation further, and explore how we can address the many challenges we face globally through the venture capital ecosystem and beyond. 

In the meantime, if you would like to be involved in the initial research of the upcoming report, please contact Jess Hill.
Solve Challenge Finals 2022: Unveiling the Entrepreneurs Who are Changing the World

After three years of virtual programming, Solve Challenge Finals returned to New York City during the United Nations General Assembly Week, grounding Solve in its ongoing commitment to the UN’s Sustainable Development Goals (SDGs). While world leaders gathered to discuss the pressing issues of our time, Solve convened the individuals and community who are poised to solve them. 

During the event,  the new 2022 Solver Class was revealed – 40 early-stage social impact solutions that are addressing this year’s Global Challenges. These individuals hail from all over the world, including Myanmar, Benin, the Navajo Nation, and more. They gathered in New York City on September 18 to pitch their solutions to our community, win prize funding, and forge connections with supporters who will continue to empower them throughout their entrepreneurial journey.

There was palpable excitement and energy throughout the event as everyone awaited the announcements of the prize winners. Over $2M in prize funding was available this year thanks to the generous contributions of supporters. Prizes were announced throughout that day and were met with loud applause, cheerful tears, and the promise of scaling our collective impact.

Read the full blog post, and Solve's key takeaways from the momentous day, here
 
Challenge Investing

Within our universe, we have a significant number of companies that are helping to profitably address vitally important global challenges. If you’d like to advise, invest in or support some of the most promising growth companies based on top research then please don't hesitate to get in touch.
Want to know more?
Contact Ed Phillips or Abi Wye at Future Planet Capital. 

 
Website
Twitter
Facebook
LinkedIn
Instagram
YouTube
Email

This monthly digest is brought to you by Future Planet Capital

This information is being communicated by Future Planet Capital (UK) Limited which is an appointed representative of Midven Limited, which is authorised and regulated by the Financial Conduct Authority.This email message and any files transmitted with it are intended solely for the addressee(s) and are considered privileged and confidential. If you have received this email in error please (i) delete it and all copies of it from your system and (ii) destroy any hard copies of it. You should not divulge, copy, forward, or use the contents, attachments, or information in any way. Any unauthorized use or disclosure may be unlawful. Future Planet Capital gives no warranty as to the accuracy or completeness of email messages and accepts no responsibility for changes made after dispatch.
 
Copyright © 2022 Future Planet Capital, All rights reserved.

Want to change how you receive these emails?
You can
update your preferences or unsubscribe from this list.
 

Xfund’s humanities graduate entrepreneurs – the next generation of success

Xfund’s Humanities Graduate Entrepreneurs – The Next Generation of Success

By Douglas Hansen-Luke, Executive Chairman of Future Planet Capital

Imagine the chief executive of a brilliant new business nurtured at a university, and you probably think of a scientist or medic suddenly transformed into an entrepreneur. For anyone looking to build an investable, high-growth company, it can seem that the best preparation is to study physics, computer science or medicine.

The reality is rather different. Scientist and medic founders play a crucial role for any university investor. The Oxford COVID-19 vaccine, for example, directly resulted from the work of our portfolio company Vaccitech – created by professors Adrian Hill and Dame Sarah Gilbert. Its work contributed to the prevention of over six million deaths in a year.

But these are not the only people who can create businesses that answer big questions and promise significant growth. In fact, in the ‘universe’ of 13,000 university-affiliated enterprises that we track, 80% were founded by alumni of institutions, rather than current academics or scientists.

Many of those founders hold degrees in the humanities – not the sciences – and some are set to make a major impact on the wider world.

New thinking and a new focus

Our focus on these founders is no accident. Too many venture capital firms try to replicate the strategies of the likes of KPCB, A16Z, or Sequoia – chasing a small pool of scientific founders in a small geography. They hope to do as well as the first movers in this field, but many fall victim to the economic rule of diminishing marginal returns. Returns generated across the venture industry tell the story: only 10% of managers match or exceed the mean performance of their peers.

A new strategy is called for, and one of our principal partners in the US – Xfund – is showing what can be achieved with new thinking. It has achieved some of its biggest successes working with humanities students. Take Kensho, the artificial intelligence start up that achieved the world’s largest AI exit in 2018. Its founder, Daniel Nadler, launched the firm while finishing his Harvard PhD not in machine learning, but in economics. His approach to technology is informed by his experience as a published poet. Poetry – he argues – can teach us how to build a better search engine.

 

The key to Xfund’s success

“That liberal arts founders are spectacular is the hypothesis that we set out to prove,” says Xfund’s Managing Partner, Patrick Chung, who numbers graduates in classics, PPE and art history among his successful founders. “And so far, knock on wood, it’s proving out.”

The idea behind Xfund’s approach is straightforward. The firm targets exceptionally bright students who have emerged from universities that boast long track records of innovation. These founders can access networks and resources associated with their institutions and create real value. The combination of their personal achievements and their universities’ standing gives investors confidence.

Investing in under-represented founders

Thinking differently about where they choose to invest has another important consequence for Xfund. It goes out of its way to seek success among under-represented founders, investing ten times more in female-led companies than the industry norm. Some 58% of their dollars have gone to startups led by women, immigrants, or people of colour.

The approach works. These investments have an enviable record of success, with Anne Wojcicki of 23andMe is their most notable female founder. By investing in humanities students and seeking out under-represented founders they have been able to write the first checks and secure meaningful positions in a stream of winning companies.

 

The power of university funds

Science-based investors will always be vital to the work of Future Planet Capital. E14 at MIT and Berkeley SkyDeck are crucially important partners to us. Xfund’s approach helps to bring an additional multi-disciplinary mix. Together they allow Future Planet Capital to pursue our own strategy of connecting with early-stage university fund partners, then leveraging the research and value from their offerings.

This way we can follow and curate some of the most exciting companies to emerge from university ecosystems and then invest during their growth stages, at key inflection points where revenues and profits are ready to scale. For us, this diverse range of founders and strategies is the best way to fulfil our vision of funding the brightest minds to profitably address the world’s biggest challenges.

 

EdTech: Back to School

*|MC:SUBJECT|*
September 2022    |    Did someone forward you this email? Subscribe Here
EdTech 2022: Back to School
As children return to the classrooms for the new school year, we want to look again at the rising investment area that is edtech.  

As you'll be no doubt aware, educational technology, or ‘edtech’, is the use of hardware and software products to facilitate learning. The edtech sector has grown rapidly in recent years; global venture capital investments in edtech crossed US$20bn in 2021, now 40x larger than it was a little over a decade ago (HolonIQ). US$87bn is expected to be invested in the sector over the coming decade (Holon IQ), with China and India anticipated to have the fastest growth.

The sector is also now firmly in the mainstream with BYJU’S, an EdTech platform worth roughly $22 billion, a major sponsor of the 2022 Qatar Soccer World Cup, the most-watched sporting event of the year.

Edtech promises reduced costs, higher quality pedagogy, and impactful outcomes beyond the traditional classroom setting. The sector now sees a diversity of segments, ranging from K-12, post-secondary, digital courseware, employment training, learning analytics, and even blockchain applications. Owl Ventures, the largest edtech VC in the world and a partner of Future Planet, highlight in their 2021 Education Outcomes Report the most exciting trends and portfolio companies addressing this important global challenge. 

There can be little doubt that edtech has emerged as a growth powerhouse, supporting the economy through investments and new jobs. We see the future only going one way - with the current edtech landscape developing further with new products, focusing on providing a more customised and personalised learning experience for users. 

Below we outline three key focus areas that we're keeping an eye on over the next academic year.
 
Click above to listen to Radio Davos from the WEF - Are your children’s toys smarter than you? Two judges at the inaugural Smart Toy Awards, musician will.i.am and UC Berkeley Professor Ron Dahl, an expert on childhood development, talk about their hopes and fears over ‘intelligent’ toys.
1. Immersive Learning
Extended reality (XR) is an umbrella term for a combination of technology with the real environment, and notably includes augmented reality (AR) and virtual reality (VR). The pedagogical benefits to consumers are obvious; an immersion in their learning that connects their personal perspective to their education. Interest and potential in XR products have risen dramatically. The market for AR in education will be over US$5bn by 2023, and VR head-mounted displays alone in education will grow to nearly US$700mn by 2025 (ABI Research). With costs for VR products lower than ever before and mobile AR/VR applications already inexpensive or completely free, the possibility for immersive learning is already here. The applications of AR and VR in education are wide-ranging and open a world of possibilities. 
 
2. E-Learning
Given our experience of the last two and a half years, this move to online learning should not come as a surprise. However, more than a temporary trend, e-learning is here to stay. Given its benefits of flexibility, affordability, and accessibility, e-learning represents a new, modern approach to how we conduct education. The global e-learning market was worth US$250bn in 2020, and is set to exceed US$7tn by 2027 (Global Market Insights), with segments as diverse as video conferencing applications, online simulator products, and online courses. The latter segment is particularly popular, with massively open online courses (MOOCs) being offered by companies like Coursera and Udemy (a 500startups company) in collaboration with world-leading universities.
 
3. Rise of AI
The global market for AI in education was worth over US$1bn in 2020, and is expected to be worth US$22bn by 2028 (Verified Market Research). AI, in tandem with machine learning (ML), enables adaptive learning; meaning teaching modulated to fit students’ needs in real time. This allows for an efficient and personalisable learning experience, with applications to voice assistants, assessment tools, adaptive interfaces and automated teaching services. Established edtech companies have already recognise the power of AI in education and with the continual rise of e-learning in the future, expect to see AI and ML being increasingly integrated into edtech offerings.
Challenge Investing

Within our universe, we have a significant number of companies that are helping to profitably address vitally important global challenges. If you’d like to advise, invest in or support some of the most promising growth companies based on top research then please don't hesitate to get in touch.
Want to know more?
Contact Ed Phillips or Abi Wye at Future Planet Capital. 

 
Website
Twitter
Facebook
LinkedIn
Instagram
YouTube
Email

This monthly digest is brought to you by Future Planet Capital

This information is being communicated by Future Planet Capital (UK) Limited which is an appointed representative of Midven Limited, which is authorised and regulated by the Financial Conduct Authority.This email message and any files transmitted with it are intended solely for the addressee(s) and are considered privileged and confidential. If you have received this email in error please (i) delete it and all copies of it from your system and (ii) destroy any hard copies of it. You should not divulge, copy, forward, or use the contents, attachments, or information in any way. Any unauthorized use or disclosure may be unlawful. Future Planet Capital gives no warranty as to the accuracy or completeness of email messages and accepts no responsibility for changes made after dispatch.
 
Copyright © 2022 Future Planet Capital, All rights reserved.

Want to change how you receive these emails?
You can
update your preferences or unsubscribe from this list.
 

A Better Future Planet: Urgent need to reduce Emissions

*|MC:SUBJECT|*
August 2022    |    Did someone forward you this email? Subscribe Here
A Better Future Planet:
Urgent need to reduce Emissions
There is no doubt that Climate Change is one of the major challenges of our time. Sadly the situation is not improving as we would hope, with the nine years from 2013 through 2021 ranking among the 10 warmest years on record. 

Human activities continue to be the main driver, primarily due to burning fossil fuels like coal, oil and gas which generates greenhouse gas emissions. These emissions act like a blanket wrapped around the Earth, trapping the sun’s heat and raising temperatures.

According to the United Nations, the richest one percent of the global population account for more greenhouse gas emissions than the poorest 50 percent.
Energy, industry, transport, buildings, agriculture and land use are among the main emitters - as we know from our newly established Blue Ocean fund, 6% of GHG emissions are also from Ocean methane.  

Emissions continue to rise and, as a result, the Earth is now about 1.1°C warmer than it was in the late 1800s. 

Temperature rise is only the beginning of the story. Because the Earth is a system, where everything is connected, changes in one area can influence changes in all others. The consequences of climate change now include intense droughts, water scarcity, severe fires, rising sea levels, flooding, melting polar ice, catastrophic storms and declining biodiversity. 

According to a report by German insurer Munich Re, extreme weather events amplified by global warming have caused about $65 billion in losses in the first half of this year, half of which affected uninsured assets. The list includes winter storms in Europe, earthquakes in Japan, floods in Australia, tornados in the US and heatwaves in most of the world. 


The Covid-19 pandemic initially resulted in a short-term reduction in emissions and reports suggest that a number of countries, including Germany, UK, Sweden and Spain, are increasingly generating electricity from renewable sources rather than from fossil fuels. This is positive, but it is clear that there is a lot more that can - and needs to be done - in this area. AI and hardware increasingly drive both investor value and impact. 

At FPC we're particularly looking at investments around the Blue Ocean, renewables and electric vehicles. With the support of clients like the Government of Monaco and the Prince Albert Foundation, we have up to 400 companies within our universe that are tackling the global challenge of climate change. We're pleased to share more information and insight with you through this newsletter. 
Anne Olhoff, Head of Strategy for Climate Policy and Planning at UNEP DTU Partnership, explains the main findings of the 2021 Emissions Gap Report
FPC's Focus on Tackling Climate Change
 
Future Planet, working in partnership with scientists and founders emerging from the world’s top universities, is seeking those companies best able to meet this challenge and address the $50 trillion market opportunity created by the challenge of climate change.   

The very essence of capitalism is to make more from less and the essence of responsible capitalism is to reduce unnecessary consumption and waste.  A sustainable approach to emissions, consumption and the environment is not only profitable but will reduce untold suffering for billions of humans and their fellow creatures. 

Future Planet brings together the world’s leading thinkers in these spaces and identities companies in focus areas most likely to make a valuable difference to climate change, reducing our environmental footprint and husbanding bio-diversity. Read below our top three insights for reducing emissions in the future. 
1. Carbon Capture & Storage "CCS"
A term that refers to technologies that capture the greenhouse gas carbon dioxide and store it safely underground, so that it does not contribute to climate change. Also known as carbon capture, use and storage, it can provide a key contribution to tackling emissions from energy intensive sectors. Furthermore, it can help removing carbon from the atmosphere through carbon removals such as bio-energy carbon capture and storage (BECCS) and direct air carbon capture and storage (DACCS) and be a platform for low-carbon hydrogen production.
2. Methane Reduction
Methane emissions from human activity are the second-largest driver of global warming, accounting for roughly 30 percent of the temperature increase from preindustrial levels. Curbing emissions of methane, therefore, will be critical to solving the net-zero equation—that is, reducing GHG emissions as much as possible, and counterbalancing any remaining emissions with GHG removals—and stabilising the climate. The five industries, which together account for 98 percent of humanity’s methane emissions, are agriculture, oil and gas, coal mining, solid-waste management, and wastewater management. 
3. Longer term... fusion and hydrogen
Many experts see fusion and hydrogen as the clean fuel of the future. It is expected that both energy sources will play a major role in decarbonizing the industrial sector. The benefits of fusion power, such as abundance, lack of carbon emissions, and energy efficiency make it an extremely attractive option. The addition of carbon capture makes the hydrogen production process nearly emissions-free, when clean electricity is used to power the carbon capture facility.
 
Climate change technology: is shading the earth too risky?
| The Economist
Challenge Investing

Within our universe, we have a significant number of companies that are helping to profitably address this significant and vitally important global challenge. If you’d like to invest in some of the most promising growth companies based on top research then please don't hesitate to get in touch.
Want to know more?
Contact Abi Wye at Future Planet Capital. 

 
Website
Twitter
Facebook
LinkedIn
Instagram
YouTube
Email

This monthly digest is brought to you by Future Planet Capital

This information is being communicated by Future Planet Capital (UK) Limited which is an appointed representative of Midven Limited, which is authorised and regulated by the Financial Conduct Authority.This email message and any files transmitted with it are intended solely for the addressee(s) and are considered privileged and confidential. If you have received this email in error please (i) delete it and all copies of it from your system and (ii) destroy any hard copies of it. You should not divulge, copy, forward, or use the contents, attachments, or information in any way. Any unauthorized use or disclosure may be unlawful. Future Planet Capital gives no warranty as to the accuracy or completeness of email messages and accepts no responsibility for changes made after dispatch.
 
Copyright © 2021 Future Planet Capital, All rights reserved.

Want to change how you receive these emails?
You can
update your preferences or unsubscribe from this list.
 

The Research Programme for The Wei Forward II launched at the House of Lords

At the beginning of the month (5th July), Lord St John of Bletso, FPC Advisory Board Member, Lord Wei, FPC Executive Chairman, Douglas Hansen-Luke, FPC IGB Member Jerry Engel, and a room full of those from the worlds of insurance, pension funds, family offices and university innovation – to name a few – joined forces to launch research programme for the second instalment of the Wei Forward Report. 

The breakfast event at the House of Lords was a great success and Douglas was able to use the meeting to update the attendees on the vision behind Future Planet Capital. Jerry, a world leader in entrepreneurship education, venture capital, corporate innovation and regional economic development visiting from San Francisco, also spoke eloquently about the importance of innovation clusters and praised FPC for helping connect such clusters around the world. Jerry also touched on how impact will be a key measurement for investors in the future, particularly as risk increases and investors work towards investments that help reduce systemic risk.

Lord Wei spoke about the success of the initial Wei Forward report, and the lessons learned from the first instalment. This included investigating the mainstreaming of impact and how to tackle the challenges of green-washing. Lord Wei also launched the research programme for the second instalment of the report and called on those in the room to get involved. 

The Wei Forward II will conduct more in-depth research into the role of clusters within the innovation ecosystem globally (insurance, sovereigns, pension funds, and others), and will share greater learnings about clusters in geographies including Asia. The second report will also consider how a greater focus on the cost of living will affect key decision makers, as well as highlight impactful solutions that help the planet in ways that are sustainable for all of us. 

The breakfast speakers were very well received by those in attendance and much interest was shown in collaborating on the report. Wide ranging questions and discussion took place, including on whether investment was encouraging greater blue sky thinking by affecting the willingness for shared ideas and collaboration; the relative role of measurement and metrics versus a more hands off approach; and inclusion and how the current system does or does not reach all possible entrepreneurs and investors (with Skydeck and MIT Solve getting a special mention for bringing founders into their platforms from around the world). 

Lord Wei concluded the meeting by thanking all those in attendance, particularly the panellists and Lord St John of Bletso who kindly hosted the morning.

Now is your chance to get involved - The second instalment of the Wei Forward Report will be drafted over the next 6 months, following a number of roundtables around the world. We very much welcome input and you can learn more or contribute by getting in touch with Jess – j.hill@futureplanetcapital.com.

Meet Dr Steven Chance, the Founder and CEO of Oxford Brain Diagnostics

Meet Dr Steven Chance, the Founder and CEO of Oxford Brain Diagnostics, the company “bridging the gap between life and death”, at the forefront of early stage Alzheimer’s diagnosis technology.

Oxford Brain Diagnostics is an Oxford University spin out that has developed unique algorithms and software, collectively called Cortical Disarray Measurement (CDM) that analyse MRI brain imaging data, giving clinicians, pharmaceutical companies and Biotechs unprecedented insights on a cellular level. The patented technology, utilising over 10 years of research, is used for the early detection of Alzheimer's disease, and also has the ability to track the disease's progression.

Global estimates suggest that 416 million people around the world are on the Alzheimer’s disease continuum, and yet there is currently no reliable way to test for AD, essential for discerning appropriate treatment. Additionally, CDM would give clinical trials the ability to more successfully diagnose and understand the patient cohort, allowing them to reliably determine the efficacy of the drug or treatment.

With their Series A round on the horizon, we spoke to the founder, Dr Steven Chance about his journey developing CDM, founding Oxford Brain Diagnostics and his future plans for the company.

“It sounds quite dramatic, but my decision to develop CDM could be described as an attempt to bridge the gap between life and death. I did my PhD in Oxford, looking at two technologies. One was looking through the microscope at tissues dissected from the brains of people who had died with disease or without disease, looking at the differences on a cellular level. The other was looking at MRI brain scans of the living and analysing in real time the changes within their brains as they were affected by disease. The frustrating gap between these technologies was that the detailed information you can see through the microscope was just not available from MRI scans. I wanted to find a way to gain access to that cellular data within the lifespan of the patient, so we could actually help them.”

OBDs primary commercial objective has always been to provide clinical diagnostics solutions to hospitals, a goal that looks set to become reality as their technology has received FDA Breakthrough Device status, prioritising their application for regulatory approval in the US.

“The Breakthrough Device status means that the FDA has not only recognised the value of the science but it is also validation for the potential of clinical use.”

While they wait for regulatory approval, analysis has already been conducted into the distribution of US hospitals, target states and distribution of the elderly who will be more at risk of neurodegenerative conditions,
Additionally, they are already gaining commercial traction with other clients across the globe.

“I think I’m most proud of having gained really good commercial traction even at this early stage because a lot of R&D companies don’t achieve that. We’ve taken a very proactive approach and have received really good uptake with pharmaceutical companies, in some cases very big pharmaceutical companies paying six figure sums to do exploratory work with us but also we have now progressed to being an endpoint for a Phase 2 AD clinical trial for one of the big Biotech firms in the USA.”

This is “only the beginning” of the potential of the Cortical Disarray Measurement technology. While Oxford Brain Diagnostics are currently focused on dementia, specifically Alzheimer's disease, the technology is applicable to an entire range of neurological diseases. Their pharmaceutical dealings include a platform sale for Parrkinson’s disease and as the company grows, they plan to launch services in conditions such as Multiple Sclerosis.

It hasn’t always been smooth sailing though as Steven elaborates on the challenge of building the perfect team.

“Getting the team together is essential and I brought in a real commercial team that had all the strengths that complement each other - I think that’s a major challenge that had to be overcome quite early on”

“I spent some time pulling together the leadership team in the company. Our Chairman, Andrew Barker has been involved with previous successful Oxford University imaging spin outs, for example, intelligent ultrasound and currently with Brainomix. So he has a lot of experience in this space and understands about the challenges that are faced when selling into hospital systems and so forth with these technologies”

“My Chief Science Officer is Dr Ged Ridgway, he has many years experience really focussed on imaging dementia - it’s his fundamental research area and he’s worked in Cambridge, London, Oxford all previously”

“My Chief Technology Officer, Ian Hardingham actually started a computer game company when he first stepped out of doing computer science at Oxford University, which was successful but he wanted to get into some more serious technology. Coming from that experience of understanding how to get something to work through the internet, across the world, in the cloud - he’s brought all that expertise to our software.”

“Finally, my Chief Commercial Officer, Omar Ehsan, has spent more than 25 years selling into pharma companies so he has really been a lynchpin in terms of gaining that early commercial traction.”

The experience of the Oxford Brain Diagnostics team is what has generated the vital difference between CDM and the other technologies in this space. Specifically Steven emphasises the importance of his research work at the Nuffield Department of Clinical Neurosciences, Oxford University neuropathology lab, spanning over 15 years.

“It’s important to know that Alzheimer’s disease is only a confirmed diagnosis at the post-mortem autopsy stage and it is the neuropathologist that provides that confirmatory assessment; until then, there is only a probable diagnosis - wrong 10%-20% of the time. What we did is we designed a technology built on that post-mortem neuropathology - we worked backwards and brought that process forwards into life. Very few, in fact I don’t think any other technologies out there have that kind of essential foundation.”

“A lot of new methods tend to approach things using AI, feeding MRI scans into machine learning algorithms. We have patented algorithms uniquely designed for this purpose based on the foundations of post-mortem neuropathology. These aren’t concepts that can purely be found or discovered by AI. There just isn’t enough post-mortem MRI data out there in the world for someone to discover the same algorithms or insights using an AI approach. ”

“Other technologies attempt to use the old-fashioned or traditional assessment of looking at brain size and volume which is the typical way people have used MRI scans in the past. As the neurodegenerative process happens at the cellular scale, there must be a huge amount of damage for that to scale up to something you can see as a sort of overall reduction in brain size.”

CDM assesses both the quantity and quality of brain tissue, enabling them to detect early markers and indicators of future change. It also means they have the “resolution to spot the differences in patterns across the brain structure” allowing them to qualify the stage that the patient is at, as well as differentiate between different kinds of dementia such as Alzheimers compared to frontotemporal dementia.
“Many other techniques purely don’t have this capability which is essential for accurate diagnosis and therefore appropriate treatment”

Looking forward, Oxford Brain Diagnostics have clear objectives as they shift into their growth phase.

“We want to achieve regulatory approval which will launch our clinical sales, particularly with the FDA in the United States. We will continue to follow that on with Japan and Europe where we have had, in some cases, surprisingly good traction setting up pilot projects.”

“We want to build on the existing Pharma and Biotech success by continuing those sales and expanding them to other neurodegenerative diseases such as Multiple Sclerosis”

“We want to gain clinical acceptance, so we are establishing pilots with hospitals in Japan, in the US, we also have an NIHR funded project here which is nice additional undiluted funding, helping to establish us within the UK hospital and NHS system”

“In the broader scope, we would look to our philosophy - rethinking brain health - and that is because the technology itself applies not just to neurodegenerative conditions but also potentially to psychiatric conditions, neurodevelopmental conditions, these are things like schizophrenia or autism. I’ve done work in those areas previously and we know we have the data, what's striking is that 25% of the entire world’s population will encounter one of these diseases in the course of their lifespan. We want to tackle this global challenge.”

Pictured Dr Steven Chance, CEO of OBD outside their offices

Pictured Dr Steven Chance, CEO of Oxford Brain Diagnostics outside their offices

Global Innovation & Local Action

*|MC:SUBJECT|*
June 2022    |    View this email in your browser
FPC: Global Innovation & Local Action
At Future Planet, our mission is not simply to deliver excellent returns but to create a lasting impact: by connecting the world's largest investors with its best minds, we believe we can address the greatest challenges that humanity faces today across Climate Change, Education, Health, Security and Sustainable Growth. 

We invest in high-growth potential companies from the world's top research ecosystems. Our global network and local strategies provide unrivaled access to companies emerging from leading academic institutions and the centres of innovation that surround them. They also help us to benchmark and assist our team members and partners operating in more localised areas. 

We have a number of world-leading advisors and partners that help us with our quest - including Jerry Engel, Adjunct Pofessor Emeritus, Haas School of Business, University of California Berkeley. Jerry is a leader in entrepreneurship education, venture capital, corporate innovation and regional economic development. Jerry is a member of FPC's Investment Governance Board and you can watch a video below which outlines some of his thinking about the role of scientists, research institutions, corporations and startups in the innovation ecosystem and how these players can successfully collaborate together. 


MIT Solve, our feature partner in last month's Future Thinking, also has a mandate that highly complements our own. They are on the hunt for founders from around the world, solving solutions locally, which they can then scale globally. For more information about MIT Solve, or how you can become a Solver, visit here.

Later this month we are also launching a number of consultations for the second installment of “The Wei Forward Report”, written by Lord Wei of Shoreditch, the social entrepreneur and Conservative peer. Lord Wei is a member of FPC's Advisory Board and we have commissioned the report to set out how venture capital can provide the solution to harnessing university-originated innovation, enabling the next generation of entrepreneurs to supercharge efforts to solve the biggest problems. You can read a copy of the first report here.

How do we connect local action to global innovation and problem solving? Over the next two months Future Thinking is going to set out exactly that. 


Please read on below to find out more - as always, don't hesitate to get in touch if more information would be helpful.
Professor Jerome S. Engel is an internationally recognized expert on innovation, entrepreneurship, and venture capital, lecturing and advising business and government leaders around the world. A Silicon Valley veteran and founder of the Lester Center for Entrepreneurship at UC Berkeley, and Investment Governance Board Member for Future Planet. Most recently he has focused on developing innovation ecosystems globally.  
Global informing the Local 

We are pleased to share with you the key ways that we work on both a global and local scale - and ensure that our insights inform each other. 
 
Benchmarking
FPC has identified and seen that some of the biggest inventions and companies with the largest potential emerge from the founders and science from the world's leading universities. However, this doesn't mean that great ideas and businesses can't be found elsewhere. We look to benchmark and connect innovation from top centres of innovation to opportunities at a local level in a number of key geographic areas. We manage a number of funds that have a specific local focus, ranging from farms in New Zealand & Australia to SMEs in the British West Midlands. 

Linking Opportunities and Market Access

Our local and global approach means that we can link opportunities at a global scale to local action, and vice versa. We can match global oversight, with specific regional knowledge which informs our investments and insights. We are also able to provide market access in areas where our teams and partners have unrivaled local knowledge.
Fostering New Centres of Innovation
With the help of our global network, including Professor Engel, we take key learnings from leading centres of innovation around the world and work to replicate these patterns in other geographies. We use these learnings to inform our processes and impact how we connect our teams and our investments, utilising our network to profitably address global challenges. 
Challenge Investing

If you would like more information or if you’d like to invest in some of the most promising growth companies, at both a local and global scale, based on top research then please don't hesitate to get in touch.
 
Want to know more?
Contact Ed Phillips or Abi Wye at Future Planet Capital. 

 
Website
Twitter
Facebook
LinkedIn
Email
Instagram
YouTube
This monthly digest is brought to you by Future Planet Capital

This information is being communicated by Future Planet Capital (UK) Limited which is an appointed representative of Midven Limited, which is authorised and regulated by the Financial Conduct Authority.This email message and any files transmitted with it are intended solely for the addressee(s) and are considered privileged and confidential. If you have received this email in error please (i) delete it and all copies of it from your system and (ii) destroy any hard copies of it. You should not divulge, copy, forward, or use the contents, attachments, or information in any way. Any unauthorized use or disclosure may be unlawful. Future Planet Capital gives no warranty as to the accuracy or completeness of email messages and accepts no responsibility for changes made after dispatch.


Copyright © 2022 Future Planet Capital, All rights reserved.

Want to change how you receive these emails?
You can
update your preferences or unsubscribe from this list.
 

Venture Capital Can Help Protect Our Oceans and Build a Sustainable Blue Economy

The ocean is a key environmental and economic resource that covers more than 70% of our planet. Despite contributing to 100 million people’s livelihoods and sequestering 80% of the world’s carbon, the ocean has been largely neglected by venture investors.

Historically, companies and projects working to protect the ocean were grant funded, but we are witnessing an influx of capital and interest in sustainable blue ocean business, known as the ‘blue economy’. Last year, Future Planet Capital committed $40 billion of capital to climate investing. Now we are seizing an opportunity to be an early adopter in the ocean impact investing space and want to encourage others to do the same.

The Future Planet Capital Blue Ocean fund, launched in February 2022, focuses on three key areas of opportunity within the blue economy: preventing pollution, preserving of marine environments and ecosystems, and sustainable marine productivity. In our investment strategy we focus not only on large financial returns, but compelling companies that make a real difference to people and to the planet. This is what’s known as impact investing.

We see clear opportunities to reduce problems in the ocean such as pollution of fishing stocks by microplastics and “ghost” fishing gear, and also in creating sustainable sources of protein, and improving the health and local economy of coastal habitats and communities through sustainable aquaculture. We also see companies innovating in the long term sequestering of carbon in the ocean, enabling renewable energy or displacing unsustainable shipping practices.

At Future Planet we look beyond simple Environmental, Social and Governance (ESG) to the positive impacts the product or service will have in an upside case. We may measure carbon reduction using a carbon pricing model, for example.

Ukraine, the Covid-19 pandemic fallout and supply chain disruption have led to rising inflation, increasing interest rates and stock market falls, all adding up to significant market uncertainty. We believe this in turn presents significant opportunities for those of us deploying capital to exceptional founders tackling the challenges in health, security and sustainable growth.

Climate change and blue economy impact investing will be well positioned in this market. Investors in this space can find true value by zoning in on the most important issues – reducing greenhouse gas emissions, finding sustainable sources of food, protecting biodiversity and creating energy sources that do not put our lives, or the environment in further danger. Injecting capital in these areas will help improve the health and wellbeing of human populations, reduce harm from the changing climate, and provide long-term financial returns. It’s a win-win.

By Ed Philips & Andy Muir, Future Planet Capital

Solve at MIT 2022: working together to profitably solve Global Challenges

*|MC:SUBJECT|*
May 2022    |    View this email in your browser
Solve at MIT 2022:  working together to profitably solve Global Challenges
The beginning of this month marked a flagship event for one of our key partners, Solve at MIT 2022. FPC and MIT Solve have worked together for the last three years - and we have an even closer partnership in the pipeline as we plan to invest for profit capital with Solve. So watch this space! 

We are pleased to be part of MIT Solve's global marketplace for social impact innovation with a mission to drive innovation to solve world challenges across Health, Sustainability, Learning and Economic Prosperity. To date, MIT Solve has brokered commitments of over $40m in funding and resource commitments from leading partners supporting the ecosystem. We are pleased to work together to ensure the rest of the world has access to one of the leading centres of innovation. 

At the beginning of May, Solve at MIT once again brought together global innovators to build partnerships and tackle global challenges in real-time alongside the Solve community–Solver teams, MIT faculty, and social impact leaders from Solve Member organisations. This includes General Motors, The Nature Conservatory, HP, The Bill & Melinda Gates Foundation. Solve at MIT 2022 convened over 300 social impact leaders including 62 Solver teams as well as thousands of virtual supporters.

The event featured plenaries where leaders from various sectors discussed the state of global issues and how technology can contribute to making us more resilient. Throughout the three days, Solver teams, Members, and supporters joined over a dozen working sessions to discuss the progress and obstacles they were experiencing, and brainstorm how to scale their impact. 

We are so impressed with the work of MIT Solve - and wanted to use this Future Thinking to highlight and share this with you.

Please read on below to find out more - as always, don't hesitate to get in touch if more information would be helpful.
Watch the Opening Plenary from Solve at MIT 2022
Solve at MIT 2022: Takeaways

We are delighted to share with you the following key takeaways from Solve at MIT 2022, as shared in their blog Solve at MIT 2022: Demystifying World Issues One Connection at a Time
 
There’s human capital at stake for every technological advancement

Technology has limitless capacity to solve some of the world's biggest challenges, but developing and deploying it comes with its own concerns. Some of the most dangerous consequences of technological development are human and land degradation. 

Impact investment does not equate to charity 

Impact investing has grown tremendously in the last decade, but there is still a misrepresentation of what it should look like. 
In the plenary, Angela Jackson, chief ecosystem investment officer at Kapor Enterprises asserted, “We invest with an impact lens but we also want returns.… I’d like to see investors think beyond [investing] because it’s the moral thing to do or the charitable thing to do, but really doing it in service of equity and in service of efficiency.” 
Start alone but don’t stay alone
There may be a time in your life when you feel compelled to solve a problem and there may be no one else available to take action with you. However, Thanasi Dilos, co-founder of Civics Unplugged and Solv[ED] judge, reminded Solve at MIT 2022 that community support leads to better outcomes. During the Closing Plenary: Young Leaders on the Horizon, Dilos shared, “Funding is great for young people, but what is really also important is community and agency.” Adding also, “No one is self-made—everyone is made in community.” 
Challenge Investing

Every year, MIT Solve hosts open innovation Challenges to source tech-based solutions to urgent global problems. The most promising social entrepreneurs from across the world are chosen to join MIT Solves' Solver class in the areas of Economic Prosperity, Sustainability, Learning, and Health. If you would like more information or if you’d like to invest in some of the most promising growth companies based on top research then please don't hesitate to get in touch.
 
Want to know more?
Contact Ed Phillips or Abi Wye at Future Planet Capital. 

 
Website
Twitter
Facebook
LinkedIn
Email
Instagram
YouTube
This monthly digest is brought to you by Future Planet Capital

This information is being communicated by Future Planet Capital (UK) Limited which is an appointed representative of Midven Limited, which is authorised and regulated by the Financial Conduct Authority.This email message and any files transmitted with it are intended solely for the addressee(s) and are considered privileged and confidential. If you have received this email in error please (i) delete it and all copies of it from your system and (ii) destroy any hard copies of it. You should not divulge, copy, forward, or use the contents, attachments, or information in any way. Any unauthorized use or disclosure may be unlawful. Future Planet Capital gives no warranty as to the accuracy or completeness of email messages and accepts no responsibility for changes made after dispatch.


Copyright © 2022 Future Planet Capital, All rights reserved.

Want to change how you receive these emails?
You can
update your preferences or unsubscribe from this list.
 

Technology: Changing the fight against Cancer

*|MC:SUBJECT|*
April 2022    |    View this email in your browser
Technology: Changing the fight against Cancer
Curing cancer is certainly one of the big challenges of the 21st century. In the UK alone, every two minutes someone is diagnosed with cancer and, according to Cancer Research UK, there are more than 166,000 cancer deaths in the UK every year, that's more than 450 every day.

Our knowledge of cancer has greatly improved in the last two decades and the development of new technology in cancer treatment is helping more and more people effectively treat their cancer and live longer, fuller, healthier lives than ever before.

We now know that huge variability can be found not only in different types of cancer but also between patients with the same type of cancer. It seems increasingly evident that there won’t be a single ‘cure’. Rather, each patient will be treated accordingly to their specific needs.

For personalised medicine to become a reality, we need a range of therapies wide enough to cover the whole spectrum of cancer. Fortunately, there has been a surge of new technologies - which we explore in detail below - which could make a big difference in the way we treat cancer, taking us closer to being able to ‘cure’ this disease.
People Who Change The World | Dr Rajesh Jena

A powerful video message about how AI is helping the fight against cancer
 
The National Cancer Institute: The Tech Revolutionizing Cancer Research and Care

What once seemed impossible in cancer research is now a reality thanks to a number of technological innovations that have led to breakthroughs in the ways we find, visualize, understand, and treat cancer.

As The US National Cancer Institute sets out, continuing to explore and use these technologies can open the door to accelerating progress against this disease.
CRISPR: Revolutionizing gene editing
Researchers never imagined being able to quickly and easily change the genetic code of living cells. But now that’s possible with CRISPR, which works like a pair of scissors that can precisely delete, insert, or edit specific bits of DNA inside cells. While it is a game-changer, CRISPR still has its limitations and debate continues around the ethics of gene editing. But one thing is clear—CRISPR is a powerful tool that could help make significant progress, in cancer research and beyond.

Artificial Intelligence: Computer programming used to improve cancer diagnosis, drug development, and precision medicine

What if a computer simulation could create a virtual model of you, a “digital twin” that physicians could use to “explore” treatments and predict possible outcomes before presenting you with personalized care options? It’s no longer science fiction, thanks to advances in artificial intelligence (AI). AI is great at finding patterns in large amounts of data, which is particularly helpful in scientific research. AI has the potential to truly transform cancer care.

Telehealth: Bringing cancer care, treatment, and clinical trials to the patient 

Providing cancer care and running clinical trials are necessities, even during a pandemic. Hospitals and clinics are maximizing safety and convenience for both patients and providers by using telehealth for remote health monitoring, video visits, and even in-home chemotherapy. Telehealth also makes access to clinical trials and cancer care easier for more diverse groups of patients across wider geographical areas. Ensuring that remote health care technology is used equitably comes with challenges, but researchers are working to address them.

Cryo-EM : Generating high-resolution images of how molecules behave to help inform cancer treatment

Cryo-EM captures images of molecules that are ten-thousandths the width of a human hair, at resolutions so high they were unheard of just a decade ago. For cancer, this means better understanding how cancer cells survive, grow, and interact with therapies and other cells. Just recently at the Frederick National Laboratory for Cancer Research, cryo-EM showed how a drug for chronic myeloid leukemia interacts with ribosomes (a molecular machine inside cells) and in the process developed the most detailed view of a human ribosome to date—an achievement that could inform the creation of treatments for cancer and other diseases.

Infinium Assay: Providing important insights into how genetic variations relate to cancer

Used by companies like 23andMe and Ancestry, the Infinium Assay, developed by Illumina, is a process and set of tools that analyzes millions of single nucleotide polymorphisms, or SNPs, the most common type of genetic variation. SNPs can help map genes that cause cancer and provide insight into cancer risk, progression, and development. Initially met with skepticism about whether this technology was technically feasible, the assay was created with support from NCI’s Small Business Innovation Research program and is a compelling instance of taxpayer-funded innovation. 

Robotic Surgery: Using robotic arms to perform precise, minimally invasive surgeries to remove cancer

A speedier recovery and quicker return to normal life—that’s what robotic surgery can make possible.  Robotic surgery involves less blood loss and pain, and a patient could leave the hospital as soon as the day after surgery. While the robotic arms may look straight out of a futuristic movie, in a setting where just millimeters could stand between removing all cancerous tissue and potentially injuring healthy tissue, their fine, precise motions can make a world of difference.

And Finally, Vaccines to Treat Cancer: Researchers are looking at vaccines as a possible treatment for cancer.

In the same way that vaccines work against diseases, the vaccines are made to recognise proteins that are on particular cancer cells. 

An antigen is a substance that triggers the immune system to respond against it. For example, a virus has antigens on its surface which triggers the immune system to attack it. Body cells and cancer cells also have antigens on them.

Tumour associated antigens are proteins found in cancer cells. Normal cells either don’t have these antigens, or if they do, they have a much smaller amount. Cancer treatment vaccines aim to help your immune system recognise these antigens. And to attack and destroy the cancer cells that have them. 
Challenge Investing

Within our universe, we have a significant number of companies that are helping to profitably address this significant global challenge. If you’d like to invest in some of the most promising growth companies based on top research then please don't hesitate to get in touch.
 
Want to know more?
Contact Ed Phillips or Abi Wye at Future Planet Capital. 

 
Website
Twitter
Facebook
LinkedIn
Email
Instagram
YouTube
This monthly digest is brought to you by Future Planet Capital

This information is being communicated by Future Planet Capital (UK) Limited which is an appointed representative of Midven Limited, which is authorised and regulated by the Financial Conduct Authority.This email message and any files transmitted with it are intended solely for the addressee(s) and are considered privileged and confidential. If you have received this email in error please (i) delete it and all copies of it from your system and (ii) destroy any hard copies of it. You should not divulge, copy, forward, or use the contents, attachments, or information in any way. Any unauthorized use or disclosure may be unlawful. Future Planet Capital gives no warranty as to the accuracy or completeness of email messages and accepts no responsibility for changes made after dispatch.


Copyright © 2022 Future Planet Capital, All rights reserved.

Want to change how you receive these emails?
You can
update your preferences or unsubscribe from this list.
 

Does Vaccination Increase Inequity?

*|MC:SUBJECT|*
 
 
 
Does Vaccination Increase Inequity?
15 Minute Read

How ironic it was that, as we sat in the gilded Coffee Room of the Cavalry & Guards’ Club, discussing arguably one of mankind’s greatest achievements, the Kremlin was poised, in the teeth of global opprobrium, to vent its demented fury on the innocent civilians of Ukraine, with all the death, destruction and human misery that would inevitably follow. We were surrounded by fine paintings reminding us of the glorious military victories of Wellington. Of course, Wellington fought for the right side, but however gloriously depicted after the event, war is always a stain on humanity.

As I was driving recently to collect my daughter from school, I had tuned in to Planet Rock on the radio (don’t worry, I am equally appreciative of the work of Tallis, Byrd and Gibbons - it just depends what sort of mood I’m in). Up came a song by Iron Maiden, one of the UK’s heavy metal titans. The song, I recognised instantly, was called, “The evil that men do (goes on and on)” - a modification of the famous line in Shakespeare’s Julius Caesar - the full version being “The evil that men do lives after them; The good is oft interred with their bones.” As we watch with horror the TV footage of Putin’s advancing tanks, we pinch ourselves to check we are actually in the 21st Century. While Shakespeare’s quote is particularly trenchant today, the opposite is also true. Jenner, Koch, Pasteur and so many others built on each other’s research, knowledge and dogged hard work over the last two centuries to bequeath to humanity a gift that brings health and life. This is still work in progress. Our modern-day heroes and heroines of science have saved us from the worst ravages of COVID-19(COVID) and given us our lives back. Scientists are the new rock stars, thrust into the limelight over the last two years. We were lucky enough tonight to be addressed by the “lead singer” and some of the other virtuosos in the band (scientists, not Iron Maiden, although that would have been highly enlightening too).

A vast amount of ground was covered this evening, from science to morality to money and many other aspects of a topic, which for the first time in modern times, is at the forefront of the minds of the general population. While we grazed the issue from multiple directions, the question that pops out at the end is whether it is both possible and right to make money out of vaccinations. The answer must surely be yes and yes. While there are certainly those seen to have profiteered during the pandemic (mostly well-connected “suppliers” of PPE), profit has not, overall, come out of this a dirty word. You could argue that vaccines are something the state should provide - and indeed it does in terms of the patient. But while it can help, the state has neither the resources nor the infrastructure to deliver vaccines on its own. We received a reminder that, while we may think we have COVID on the run, there could be long-lasting effects and continued protection through vaccination is essential.

COVID may have shaken the world, but the flip side of the coin is that, necessity being the mother of invention, it turbocharged the whole science of vaccination. The billions of COVID vaccines yet to be produced and sold around the world are merely the tip of the iceberg. Could we have dared to dream that what traditionally took ten years can now be done in 12 months? In the dark days of 2020 this dream was indeed distant, but reality miraculously overtook the dream. In fact, as we heard this evening, the industry aspiration is to bring that down to 100 days or even less. Yes, this will protect us so much better against inevitable future pandemics, but that is just the beginning. With the technological advances made in the last two years, particularly in RNA, vaccinations for myriad serious diseases are now within our grasp. As national health services groan under the weight of ageing populations, the maxim of prevention being better than cure will come to the fore. Prevention of chronic diseases will save literally trillions of dollars over the next 10 years. Governments and investors alike will want to be involved in this paradigm shift in healthcare, craving exposure to the vaccination phenomenon. This is surely where the smart money is heading.

Are you sitting comfortably? Then we’ll begin...

Ed Harris - ThoughtLeader Editor
Summary of ThoughtLeader Dinner, Tuesday 22nd February

Introduction from the Sponsor - Douglas Hansen-Luke - Chairman of Future Planet Capital
 
Future Planet Capital (FPC) was set up 6 years ago with the purpose of investing in the brightest minds on the planet from top universities and centres of innovation and research to invest in companies that could profitably address the key challenges currently facing the world. Two years ago, FPC invested in Vaccitech which was set up by Professors Hill and Gilbert of the Oxford vaccine. This vaccine has changed the world, being the most commonly used during the COVID pandemic. This has been done at some 10% of the cost of its competitors and has arguably saved more lives than any other. They are essentially investing in peace and healing. In the last year, they have also started collaborating with Professor Dan Peer of Tel Aviv University, who developed the first lipids that went into the BioNTech vaccine. Tel Aviv University has now set up a lab in Harwell, Oxfordshire. The objective is, with the help of the UK government, to create a vaccine which is effective, trusted, equitable and, of course, profitable. Therefore, tonight’s debate focuses on whether such things can be done both equitably and profitably.
 
Introducing tonight’s speaker
 
Professor Sir Adrian Hill was originally a medic but then moved on to biogenetics and founded the Jenner Institute in 2005. He has been at Oxford University for over 40 years and is of course best-known for heading the Oxford vaccine team. However, his start point is actually malaria and next year we hope to see the launch of a malaria vaccine, which will be a major global event. He is the Lakshmi Mittal Professor of Vaccinology and outside the lab has a passion for rugby and ballet.
 
Before Sir Adrian gave his exposition, nine pre-prepared scripts were read by members of the audience to set the scene for the forthcoming talk.
 
Script 1
 
2020 will be remembered for many things: deserted streets; skies without planes; and a glorious Mediterranean summer. It was also a year of restrictions, unprecedented in our lifetime. According to Dictionary.Com, the word ‘unprecedented’ was voted ‘Word of the Year”. One morning in October 2020, the word appeared in the frontpage headlines of eight national newspapers. In the Oxford English Dictionary, ‘unprecedented’ is described as follows:
 
“Without instance, never before known, unparalleled”.
 
The pandemic of 2020 was many things.  However, one thing it was not, was unprecedented.  
 
Script 2
 
Eighteen hundred years ago, a city in the heart of Europe was in the midst of a plague many times more deadly than the one we suffer today. That city was Rome, and the disease became known as the Antonine Plague. Victims would endure a viral attack for several weeks with progressively awful symptoms, too revolting to describe at dinner. It would prompt a contemporary writer at the time to say:  “Like some beast, the sickness destroyed not just a few people but rampaged across whole cities and destroyed them”. 
 
Script 3
 
There were seventy-five million people living in the Roman Empire at that time.  It is estimated that ten million died in the Antonine Plague. It swept across the land indiscriminately. The elite, the rich and the poor, all succumbed to its ravages in equal measure. In AD 167, there was no defence against a viral attack, there were no epidemiologists, and no understanding of what was happening, and how to stop it. So, they prayed to their gods and hoped. Some even sent delegations to Apollo, asking for his advice. There was no Chris Whitty in Ancient Rome. Marcus Aurelius, who was popularised in the film Gladiator, described the Antonine Plague in his book, Meditations, as follows: 
 
“To bear in mind constantly that all this has happened before and will do again – the same plot from beginning to end, the identical staging.  All just the same. Only the people are different.”
 
How right he was.
 
Script 4
 
For eighteen hundred years, plagues, pandemics and disease left their cruel stamp on mankind time and time again. The Black Death raged across different continents three times between the 5th and 19th Centuries. Fatality was counted in millions, in some regions populations halved, villages disappeared and the course of history changed forever. Then, in 1918, the Spanish Flu infected 500 million people worldwide, killing 100 million in 18 months. Cholera, Yellow Fever and Polio all left their mark. But perhaps the deadliest of all was the Smallpox virus. Believed to have been in existence for three thousand years, it is impossible to calculate exactly how many perished over time.  However, it is estimated to have killed at least 300 million in the 19th and 20th centuries alone. 
 
Script 5
 
Today, we owe a huge debt of gratitude to a doctor practising in a rural English village towards the end of the 18th Century. Growing up, he heard that milk maids, who were renowned for their beautiful complexions, frequently contracted cowpox from the animals they tended, but typically did not get smallpox. Taking the liquid matter from a cowpox sore, he scratched it into the skin of an eight-year-old boy, who had smallpox. After a few days, the boy recovered. He named the matter taken from the cowpox sore ‘Vaccine’ after the Latin word ‘vacca’, meaning ‘cow’.
 
Script 6
 
That doctor’s name was Edward Jenner, and his discovery began the long journey towards the eradication of smallpox and the prevention of many deaths. In 1806, US President Thomas Jefferson wrote to Edward Jenner saying, “You have erased from human afflictions one of its greatest. Yours is the comfortable reflection that mankind can never forget that you have lived. Future nations will know by history only that the loathsome small-pox has existed and by you has been extirpated”. In 1967, a massive search and vaccination programme began with the aim of eradicating smallpox. It was a truly global effort. Ten years later, smallpox was finally declared eradicated.
 
Script 7
 
It took one hundred and fifty years to truly extirpate smallpox. Notwithstanding the research and development already in place, it has been an extraordinary achievement to create, manufacture and distribute an effective vaccine program against a novel virus in just two years. Perhaps one might even say it is ‘unprecedented’. Yesterday, Bloomberg’s COVID-19 Tracker System showed that a remarkable 10.4 billion doses of vaccine have been administered worldwide so far. However, it is concerning that vaccine dose rates in the most developed countries average 200 per 100 people, while in less wealthy countries that figure falls to around 30, and, in some of the poorest countries, 6. It is no surprise that health officials at the World Health Organisation now refer to COVID-19 as “a pandemic of the unvaccinated”.
 
Script 8
 
To help conceptualise the sheer number of viruses in existence, consider this: their current biomass has been estimated to be the equivalent of 75 million blue whales and, if placed end to end, the collective length of their virions would span 65 galaxies. Tom Freidman, the American political commentator and Pulitzer Prize winner, urged us not to get too complacent when he wrote - “Vaccines and antibiotics have made many infectious diseases a thing of the past. We have come to expect that public health and modern science can conquer all microbes. But nature is a formidable adversary”
 
Script 9
 
Dr Eric Yager, microbiologist at Albany University, said in November last year: “This pandemic has ushered in a new era of vaccine research. The combination of global collaboration and the development of mRNA vaccines is akin to a ‘landing-on-the moon moment’.“ We have come a long way since milkmaids and cows. But, as an unattributed source once said: ‘There is nothing so patient, in this world or any other, as a virus searching for a host’…
 
… Let’s find out more.
 
The Chairman had polled the guests as to their view on the motion. The result was 40% for, 60% against.
 
 
Professor Sir Adrian Hill - Director of the Jenner Institute and Lakshmi Mittal Professor of Vaccinology at the University of Oxford, Fellow of Magdalen College, Oxford. Leader in the field of malaria vaccine development and co-leader of the research team which produced the Oxford–AstraZeneca COVID-19 vaccine
 
Poets have been strangely silent on the subject of vaccines. Wordsworth would probably have been aware of the work of and quite possibly personally known Edward Jenner, but never a word about vaccines - just daffodils! 
 
It has been an extraordinary two years for the whole world. Even pre-pandemic, the effects of vaccines should inspire awe, surprise and appreciation. They are doing an extraordinary job. 25 years ago, twice as many children died of infectious diseases as do today. This is largely due to the deployment of highly-effective, safe vaccines. 11 vaccines are now administered to children across the world from the wealthiest countries to the poorest regions of the developing world. There is around 90% global coverage of infant vaccines - something that would have been a game-changer during COVID. It is cost-effective because by the time these vaccines are delivered to the poorest parts of Burkina Faso, they have been licensed in rich countries where prices are much higher and manufacturers, mostly in Asia, have found a way to produce them at vast scale on thin profit margins, but still profitably. This makes them affordable for even the poorest countries. 
 
This is a clear view on whether vaccines increase inequity. They generally do not as they are daily saving the lives of some of the poorest children in the world. This is achieved through a differential pricing model which is somewhat bizarre. 80% of the value of vaccines comes from high-income countries vaccinating roughly 10% of the number of people being vaccinated in low-income countries. This system was never planned but has evolved into one that works very well. 
 
So therefore, in normal times, vaccinations cannot really be said to increase inequity. However, when COVID arrived, a coalition of international entities that arranged vaccinations - the WHO, UNICEF, GAVI (The Global Alliance for Vaccines and Immunization), and the newly-formed CEPI (The Coalition for Epidemic Preparedness Innovation) came together with a very sensible, attractive scheme called COVAX (COVID-19 Vaccines Global Access). All manufacturers would provide as many doses of vaccine as quickly as possible and these would be equitably distributed around the world. Last year, 9.5bn doses were distributed globally - an unprecedented achievement in this field. One might think we had now achieved a solution for all future pandemics. Of course, that would sadly be a Panglossian assumption. The key problem is inequity of vaccine distribution.
 
What went wrong? The distribution was both chaotic and extremely unfair. There was no globally-agreed distribution system. Such a task had never been undertaken in such a hurry before. There was a bidding war and naturally some countries could afford more than others. Some were better organised and, therefore, able to secure supplies before later bidders. As of now, only 16% of people in Africa have even had a single dose, compared to 80% in the UK and 99% in some countries. Costs have varied significantly; the Indian government was paying $1.50 per dose from the Serum Institute of India, up to $30 for the new mRNA vaccines. This was not what COVAX was trying to achieve. Nationalism also tainted the process. As it happened, the three countries with the largest militaries in the world - China, Russia, and the US, were also the three countries that did not license any vaccines other than their own. Theirs were each clearly the best so no need to license any others. They can’t all have been right. 
 
When it comes to such a global emergency, you think of the big pharma companies and how much profit they are going to make. Four of them predominate in vaccine supply to high income countries - two in the US and two in Europe. In the end, only one of those became a major player in COVID-19 vaccines, which teaches us that we cannot always rely on big pharma to produce all the vaccines needed. Even the ethical question of “What is the right thing to do?” was not clear. The Chinese were criticised for prioritising their military for early vaccinations. Some vaccine manufacturers in Asia were vaccinating their own staff before distributing it externally. Most of those early vaccines had very little safety or efficacy data and these players were condemned for their actions. In the movie Contagion, that is precisely what the lead scientist does - injects herself before anyone else. Is that ethical? If the next pandemic were to be as deadly as Ebola - killing 60% of those affected, would you not expect those producing the vaccines to vaccinate themselves first? This is something the world needs to consider rather than just throw stones at each other.
 
In terms of distribution, several countries have individually consumed more COVID vaccine than the entire continent of Africa (consisting of 54 countries). That is hardly equitable. But how can that be corrected? The Africans are understandably furious and are trying to set up their own vaccine production facilities, but it is too late. So, while in normal times, vaccines generally are equitable, during the COVID-19 pandemic there simply wasn’t time to set up a system that prevented selfishness.
 
Vaccine technology is amazing and the COVID vaccines were a triumph of that technology - in particular, mRNA, which, to most people, appeared out of nowhere (in reality, decades of research went into it). This was also good for viral vectors - before COVID only one viral vector had been licensed in the West - J&J’s Ebola vaccine. Even the old-fashioned inactivated vaccines with which Louis Pasteur would have been familiar have done very well for what they were designed for. The standard way of producing vaccines - expressing a protein, finding an adjuvant, mixing it in - has turned out to be far too slow for a pandemic. That has been a complete surprise. 
 
Ironically, the triumph of mRNA vaccines has further increased inequity due to the temperature requirement of the early mRNA vaccine. Poorer countries simply do not have the infrastructure to store and distribute vaccines at -80C - it worked fine in Europe and the US. Therefore, RNA vaccines must quickly address the issue of thermostability, which is why it is so exciting that the NeoVac initiative may well have solved this problem. That would be a huge step forward in terms of the fairness of distribution of RNA vaccines. In conclusion, in a pandemic situation, global public health policy collides with market economics, creating unfairness. Technology will play a key role in the solution - we need more facilities and more, newer vaccines. It is this that we must work on ahead of the next pandemic which sadly will inevitably come at some point. 
 
The exposition was then followed by contributions from other experts.
 
Professor John Oxford - Professor at Queen Mary, University of London - leading expert on influenza, including bird flu, the 1918 Spanish Influenza, and HIV/AIDS.
 
The Past
 
A cataclysmic 100m people died from Spanish flu (so far 5m have died from COVID). A Viennese neurologist and fighter pilot - Constantin von Economo - in 1918 had mostly young men coming through his practice with head injuries from the war. Suddenly, his clientele started to change. He was increasingly seeing young men and women (the Spanish flu, unlike COVID, was predominantly fatal for the young aged 18-35) apparently suffering from Parkinson’s disease or cerebral palsy - shakiness, lack of balance and general weakness. They also suffered from intense lethargy and sleepiness - encephalitis lethargica. Within a few months, some French neurologists saw patients with similar conditions and soon these were occurring all over the world. By 1925, there were 5m cases of Von Economo’s disease across the world. Curiously, it was not contagious and nobody knew how one got it. 
 
In the early 60s, another neurologist Oliver Sacks arrived at a hospital in New York. He was asked to look after a group of survivors of Von Economo’s disease, some of whom had been on the ward for 25 years. They were barely conscious. L-DOPA had recently been successfully used to treat Parkinson’s sufferers, so Sacks thought there would be little to lose by trying it on these patients. As described in his 1973 book “Awakenings”, these patients literally came back to life. Ladies who could play the piano 40 years ago could still play and they all spoke with their accents of 40 years prior. However, this miraculous effect was short-lived and the patients were, within weeks, back in their semi-catatonic state. Sacks thought that increasing the dose might help, but that was not possible.
 
A pair of epidemiologists from Atlanta, Georgia published a paper in the Lancet suggesting these patients were suffering the after-effects of infection with Spanish flu in 1918. The virus had got into their mid-brain area, either damaging it and leaving or possibly remaining there. Scientists probed brain and lung samples for definitive influenza RNA without success, but this was nonetheless a plausible explanation. Oliver Sacks turned out to be the key player in demonstrating that you can have a rare, long-lasting neurological impact after a large flu outbreak. A similar phenomenon also occurred with measles before MMR. A child would get measles and apparently recover. Then some time later, they would start to exhibit these same symptoms and ultimately die. Autopsies would show traces of measles virus in the brain. Of course, thanks to vaccines, children don’t get measles anymore. Likewise with polio, effects could be seen up to 30 years later
The key question now is whether COVID has a similar sting in its tail. It is a very strange virus. Unlike with other flu viruses, patients are not dying of pneumonia - it is from an as-yet poorly understood reaction of the immune system. The key point about this, therefore, is that we cannot be complacent about COVID-19. Just because fewer people are dying, we may yet find in the future that some who have caught it and recovered are still harbouring latent conditions that will present at a later date. In particular, we need to be wary of children catching it. While they do not appear to suffer at the time, the seeds of serious future illness may have been planted. Some scientists today feel like Cassandra - the Trojan priestess cursed to be able to tell the future but never to be believed. In truth, we will not know for four or five years yet whether COVID-19 is really over or not.
 
Professor Dan Peer - Director of the Laboratory of Precision NanoMedicine at Tel Aviv University
 
The future
 
His lab was the first to show systemic delivery of mRNA in animals. This was some years ago and felt like science fiction. However, its transition to reality was rapid. He wrote a grant in 2008 to the National Institute of Health entitled “mRNA which is modified with lipid nanoparticles as a new platform for vaccines.” There was almost no interest whatsoever. The comments from the panel were effectively that it was imaginary, could not be done and an altogether stupid idea. In December 2020 when the Pfizer vaccine was approved, he was able to remind the NIH panel of their earlier comments. 
 
They were approached by BioNTech to collaborate on some of their lipids, which resulted in a few licensing deals and the rest is history. The key is the future. We have learned over the last two years the challenges in making really good mRNA vaccines, key among which is thermostability. They must be stable in a regular fridge or even at room temperature. Also, the ability to entrap large payloads in lipid nanoparticles opens up new avenues for so many diseases - not only regular infectious diseases but also cancer, and metabolic diseases. But even in the sphere of regular infectious diseases there is so much scope to create new and better vaccines. 
 
They have developed a proprietary new lipid library which they have started testing. Around a year ago they came to the UK and set up, with Adrian Hill and others, Neovac. It has huge potential. The ability to entrap large payloads into a single particle is already at the ‘proof of concept’ stage. Thermostability for at least one year in a regular fridge or one month at room temperature is an ongoing study. This could change the world.
 
Marianne Talbot - Director Of Studies in Philosophy at the University of Oxford's Department for Continuing Education
 
The human aspect
 
Most of us were brought up both to tell the truth and be kind. However, life throws up plenty of moral dilemmas when these can be mutually exclusive (when your mother asks your opinion on her terrible haircut, for example). The COVID-19 vaccine has created various moral dilemmas; we ought to protect people in our own country. However, we also ought to protect those in poor countries who can’t afford to protect themselves. Given a finite number of vaccine doses, you cannot do both. Many different interests impact on these decisions. 
 
The second moral dilemma; we ought to protect our most vulnerable citizens, but we also ought not to force citizens to do something against their will. If we are to look after people in care homes, then surely both carers and patients must be vaccinated. What if the carers don’t want to be vaccinated? Do we force them? Also, given that none of us are safe until all of us are safe, do we introduce vaccine passports and, if so, are we prepared for those who don’t want a vaccine to be denied access to clubs, restaurants and foreign travel? Is that not unfair coercion? 
 
There are different approaches to moral dilemmas; we can insist that one “ought” is more important than the other - for example, that truth-telling is always more important than kindness. Alternatively, we can decide that kindness trumps the truth. We all know people who exhibit both philosophies. The answer is that each situation must be judged on its own merits. Do we prioritise vaccination for children in the UK who appear to be unaffected by COVID, or the elderly in poor countries who are?
 
The other approach to the moral dilemma is to reinterpret the key concepts. In the case of Mum’s bad haircut, telling her the truth about it can be rationalised as being cruel to be kind, so we have ticked both boxes. We could conversely say that, if we lie in this case it is not a real lie - just a white lie. In the case of vaccines for carers, we can approach the question by saying that we are not forcing them to be vaccinated insofar as we are not forcing them to be carers. Equally, with vaccination passports, we present the restrictions imposed on the unvaccinated as being their free choice. 
 
Moral rules will often clash, but that forces us to think about our values - what is a lie? What is it to be kind? What is it to protect people? What is it to force people to do things etc.? Aristotle took the view that there are no moral rules, but that we need to engage in moral reasoning. This is an ability exclusively enjoyed by humans. COVID-19 vaccines have faced us with a number of moral dilemmas. We have no choice but to deal with them while trying in some way to keep all the virtuous qualities in play. 
 
Jules Haggerty - Head of Centre of Excellence - Lipid NanoParticle at CPI (Centre for Process Innovation)
 
Public / private collaboration
 
How can we use government-funded infrastructure created over the last 5-10 years to support and accelerate medicine and vaccine development? In early 2020, the UK biomanufacturing community was already mobilising - this was before the vaccine taskforce was even thought about. This close-knit community set about finding out who had which relevant capabilities in terms of RNA vaccine manufacture and distribution. It turned out there was not much. By chance, CPI had just been doing some work around lipid nanoparticle technologies that would lead to RNA. CPI thus turned out to be the best qualified entity to take care of UK manufacture and supply of the RNA once the taskforce was convened. Their first project was a collaboration with Imperial College which worked well. The fact that for their clinical trial material they had to source RNA and other materials and technology from the USA and Austria did demonstrate that there wasn’t much to work with in the UK. It has been a rollercoaster few years working with the Vaccine Taskforce with changing strategies and partners. However, running through all their work was a strong desire to be able to manufacture and supply RNA vaccines from the UK and not be reliant on sources abroad. In that they succeeded. They have engaged in R&D and set up a manufacturing facility in Darlington for a fraction of the cost of most other manufacturing facilities. 
 
What will they use it for? CPI only exists to partner and collaborate. They will be translating academic research and help companies grow to the benefit of society and help economic growth in the UK. The Darlington facility will be offered out to the new generation of companies to progress their vaccine candidates into the clinic as quickly as possible. In this pandemic, quick decisions had to be taken and regulators had to be nimble. The government found a new way of making decisions without going through 20 layers of bureaucracy. If they could do it then, then why not now? You have to take more risks and do things in parallel. You need finance up front, but it’s not impossible. 
 
CPI’s collaboration model tackles the really big challenges that trouble industry and society. It is competitive, but academia, government and industry can work together using a shared risk and reward model. It demonstrates the art of the possible. When finance is needed, there is already a proof of concept in place. An example is CPI’s collaboration with NeoVac. The vaccines taskforce asked them to survey the UK landscape regarding RNA and lipid nanoparticles to assess what was extant and what was missing from our capabilities. Equity was a big issue - the vaccine cannot be $30 a dose around the world. Equally, the UK government did not want to be dependent on one overseas company demanding licence fees for a proprietary lipid. NeoVac has some IP (Intellectual Property) that really addresses some of those key issues. Combining the manufacturing capability and RNA supply of CPI with NeoVac’s IP portfolio will demonstrate proof of concept. This goes way beyond COVID. The LNP (Lipid NanoParticle) technology is useful not just for delivering RNA but also lots of next-generation therapy - the list is endless. 
 
Christopher Egerton-Warburton - Partner at Lion's Head Global Partners
 
Costs
 
When the UK government wanted to fund GAVI (Global Alliance for Vaccines and Immunization), IFFIm (the International Finance Facility for Immunisation) was at hand. It was founded in 2006 on the idea that private investors and government donors can work together to have a greater, more immediate impact on global health. This entity devised a way to issue bonds to fund vaccines. Following the Ebola crisis, he was contacted by a major WHO figure, who had also co-founded GAVI, reminding him of Bill Gates’s famous remark to Angela Merkel that “This should never happen again.” Out of this, CEPI was formed which crystallised his thoughts on what needed to be done to bring new vaccines to the world.
 
The focus of GAVI is cost - how can vaccines be made cheaper, to the point where most Western manufacturers have largely exited the space and bulk manufacturing has moved to developing countries such as India, where it can be done at incredibly low cost. Lives are saved literally for pennies. It has been incredibly successful and the UK has been a huge supporter of GAVI. Early in the COVID-19 outbreak, he was invited to join a meeting at the World Bank in Washington. There were a surprisingly small number of people there trying to figure out what on earth to do about COVID. This was the nightmare they had been fearing and they realised they were not remotely ready for it in terms of products and science. The UK had not joined CEPI, but thankfully Chris Whitty had helped set up a similar body which had channelled funds into the Jenner Institute and others. 
 
He was asked to write a paper for the Bill Gates Foundation on which vaccines he believed would make it. His initial thought was that COVID-19 had come too soon for mRNA technology - that governments and regulators would not be prepared to allow these vaccines to be administered to millions of people without years of trials to test for secondary impacts etc. Normally, regulators are particularly cautious about vaccines, lest they make otherwise healthy people ill. Vaccines do not change. The BCG (Bacillus Calmette–Guérin) vaccine against TB hasn’t been changed since 1918. 
 
There was a concept at GAVI that vaccines should be free. This came from enlightened self-interest. It is not just about saving people in poor countries - it is also about preventing infectious diseases from migrating from poor countries to rich. COVID-19 presented a complex horror story. All vaccines had to be free. Everybody had to be vaccinated. Imagine the difference in cost between vaccinating a cohort of people and jabbing the entire population of the globe. HPV (Human papillomavirus vaccine) almost completely prevents cervical cancer in women and throat cancer in men. However, because this was only rolled out year by year, millions in the future will die from vaccine-preventable cancer. So, the task of rolling out for free a vaccine that did not yet exist to everyone on the planet was a daunting task. 
 
His sense in writing this paper was that the Oxford vaccine would probably be the best candidate but spoke to Adrian Hill to tighten up a few facts. The rest is history. There is more to do, however. The vision must be to be able to create a vaccine in 100 days. Much of that is about regulation and the realisation that we already have some good tools and models. CEPI set up many models on the basis that of 20 vaccines, 15 would likely fail. What is actually more likely is that either all would succeed, or all fail on the basis of whether or not they produced an effective protective antigen. COVID-19 has arguably fast-forwarded biochemistry by 10-15 years. We must now take what we have learned, in order to ensure that vaccines are equitable. 
 
He suspects that when the history books are written, the Oxford Ebola vaccine would have been one of the best, even though it never got licensed. Novavax is probably the best COVID-19 vaccine we have created, but represents only a fraction of doses administered. Science is not fair. mRNA vaccines have been shown to be a very powerful tool in shutting down an epidemic. If such vaccines can be made cheaper and more thermostable, then the inequity question disappears. 
 
Q & A session
 
Q         How can we avoid forgetting what we have learned so that when this happens again we avoid the same mistakes?
 
A         History does repeat itself. Ebola did not only occur in West Africa. People brought it back to the UK, were quarantined, ended up in ICU and some sadly died. At that time, some money was made available - it conjures a rueful smile to think how generous David Cameron’s government felt its £50m contribution was, albeit that it was later doubled. We need to develop all technologies that we have and we know so much more in the wake of COVID. The main thing, and this is not hugely expensive, is that we need to build proper manufacturing facilities. What made a huge difference to the Oxford team was that they had already been working with the world’s largest vaccine manufacturer (AstraZeneca) on a more obscure disease, so when COVID-19 arrived in March 2020 and the Oxford vaccine was licensed nine months later, this collaboration was already well-established. Even in mid-2020, the Gates foundation was talking of funding manufacturing facilities in each continent to help in the struggle against COVID. This went a bit quiet when someone was brave enough to point out that these would take two years to build and a third to get them approved. Then they would have to be staffed with people with considerable experience of manufacturing vaccines - all in, a rather complex process. These facilities do indeed need building across the world in preparation for the next pandemic. It will cost money but is more cost-effective than certain other defences. We are more likely to have another pandemic than a nuclear war (Adrian might revise his thoughts on that given events since then). The circumstances that gave rise to this pandemic are still there. We should perhaps focus more on health and less on war.
 
Q         How do we devise incentives for the vaccine industry to produce one-shot vaccines which would necessarily have hugely front-loaded sales?
 
A         There are several ways to go. Thermostability is crucial - if you can store vaccines in a fridge for a year, that would be ground-breaking. Take the example of Israel. Early in the pandemic, there was a strategic decision to strike a deal with all the companies developing vaccines. They all got paid, despite there not yet being a vaccine to deliver. They were effectively buying the rights to priority distribution of the future vaccines, and it worked for Israel strategically. The price, of course, was very high. 
 
There are ways to reduce risks. People had not appreciated the scale of the thermostability issue. Specialised containers are being produced that help with this. 
 
Q         This is a question about Biosecurity. The scientists in the room obviously are driven by good intentions. As we are seeing in Ukraine, not all people share those good intentions. Looking back in history, gas - the first weapon of mass destruction - was used in WW1. Between the wars, there was a preoccupation with sarin gas. Thankfully, it was never used. Then 1945 saw the creation of the nuclear bomb. We went through the Cold War during which the destruction of the whole of society was a very real possibility. We have now reached an age where biological weapons can be deliberately delivered and deployed by actors with aggressive intent - something that can spread swiftly through a society and have a high mortality rate. While we are in the fortunate position now with COVID-19 being a relatively mild disease, despite its high transmissibility, it is highly questionable as to whether this was a disease that evolved naturally. Is it now not the job of the nation state to create a biosecurity construct whereby potential biochemical threats, particularly from the likes of China, are analysed and antidotes developed and manufactured, in tandem with the development of vaccines against naturally-occurring diseases?
 
A         There are already thoughts along these lines. There are strategies for producing expensive antibodies or vaccines along “pancoronavirus” lines. Luckily, there are only seven classes of pathogen, and it will soon be possible to create generic vaccines against many of them. Until COVID, the only people who cared about coronaviruses were veterinary vaccinologists. They were a huge problem for chickens and other livestock and many vaccines were developed for them, but humans had only mostly encountered SARS and MERS. Sitting around the table, we were all no doubt infected by a variety of coronaviruses which thankfully don’t cause much disease. We should be reassured to know that it is actually very difficult to create bioterrorist agents. You have to be able to test them to see if they are more transmissible and virulent. COVID-19 has been through billions of people over the last two years, mutating all the while, and it has taken quite a while for it to mutate into something highly transmissible. We are lucky that its virulence has been reduced.
 
Q         Was Brexit a pro or a con when it came to Europe’s “Vaccine Wars”?
 
A         The scientists involved in the Oxford vaccine were adamant that it should not be labelled a “British” vaccine draped in the Union Jack, despite the fact that the UK government largely funded it. It was unfortunate that a German tabloid in particular decided to run a story that the Oxford vaccine was ineffective. This may indeed have been symptomatic of Brexit tensions. Although this resolved itself in the end, it certainly dented vaccine confidence in the short term. One key revelation, though, in terms of policy is you should not listen to the groups of academic experts in any one country. Instead, you should listen to the regulators in each country as they communicate amongst themselves constantly on questions of safety. The groups of academic advisors changed from week to week. The newspapers didn’t want to publish the findings of the regulators - only the most extreme views on both sides.
 
Q         Tonight’s debate is about equity - what works and is fair for everybody. Is it right for a country to pursue the safety of its own people ahead of others? Is there a way in which government can speed up the process and what is it about nationalism that makes it so hard for countries to cooperate? 
 
A         The Israeli experience proved to be highly efficient. Only 9,000 people died from COVID. This number was very similar to two bad years of ‘flu. Starting vaccination very early in December 2020 brought Israel very quickly to a high level of protection. They paid more than treble the retail price for what at the time was a risky technology. There was criticism and dissent within the government, but the result was that Israel’s five waves of infection did not do too much harm. Angela Merkel negotiated a great price with Pfizer BioNTech, but that meant Germany was the last to get the vaccines. The founder of BioNTech didn’t himself get vaccinated until it was “his turn”. The outcomes of these different strategies tell their own story. Israel arguably suffered almost no excess deaths from COVID.
 
The UK also started vaccination early, but our death rates did not stay low. Why? The perceived compliance of the British public? The decision to lock down a week later than advised may have had a profound effect. There is no point in giving people three doses of vaccine against a particular variant when the virus is rampaging and mutating around the world. It would be better to be a little more generous in our distribution overseas. We should increase our help to developing countries in setting up their own manufacturing facilities - this can be done without losing control of our IP. 
 
Adrian has dreamt of countries producing vaccines A, B, C and D with nobody knowing which one was from where. When we go to the GP to get any other vaccines, we don’t ask or know who made them and in which country. Our only concern is whether they are effective and so it should also be with COVID-19 vaccines.
 
Q         What lessons around equity and access learned from vaccines can be applied to other life sciences and pharma? In these other areas, because there is less reliance on public / private partnerships and more on private financing through pharma companies and recovering the cost of research through the patent process, there are questions about where the research effort is directed. Imperfect though equity in vaccines may be, it is better than that in the rest of pharma, even from the perspective of being a champion of the role of private pharma in innovation. It has nonetheless been highlighted that there is a lack of research effort in combating antimicrobial resistance and producing new antibiotics. How do we achieve an effective direction of research dollars across the life science sector?
 
A         We live in a capitalist society - we have to work with the system. We heard about the massive bet that Israel made on the COVID-19 vaccines. These are not the sort of decisions that governments usually make. In normal circumstances, such a gamble would likely prompt too many recriminations. Over the years, big pharma like GSK, Pfizer, Merck and others have received bloody noses by pouring money and capacity into various vaccines. We need these big companies and they have shareholders. Ultimately, we cannot expect them to act against their own interests.
 
We can learn things from RNA in that it is a platform technology that can be applicable to the 100-day challenge. That is applicable to a range of other therapeutic uses. There could be technological transfers that may have an impact in reducing costs. The issue of funding is more difficult. Big pharma’s programmes are pre-arranged. If they are working on a malaria programme you can’t suddenly ask them to produce a cancer therapy available at a particular cost. This could be an area where more charitable and philanthropic organisations can step in. 
 
Q         Money has poured into the development of COVID-19 vaccines in the last two years. Are there any other areas that might benefit from a spillover effect?
 
A         Closely related areas like flu may well benefit but it is also possible that the likes of shingles and HIV could also benefit. The next step could well be cancer. Many of these RNA companies were based in cancer research and they might go back to that - for example specialist tumour vaccines. The other areas might be protein-replacement therapies such as cystic fibrosis and other genetic disorders. The technologies are applicable, but manufacturing would need to be scaled up. 
 
Q         What is the prognosis for the malaria vaccine?
 
A         The vaccine for Plasmodium falciparumis - the most widespread and deadly (640,000 deaths in 2020) strain is in phase III trials. Efficacy is currently at 70% - we would like it to be at 95%. There is a vaccine from the Serum Institute of India - made in Oxford. Their approach to malaria is not to push one but four and, subject to funding, the main principles have been cracked. The other good news is that they can manufacture it at about $1 a dose.
 
Summations for and against the motion:
 
For (proposed by your editor)
 
This title does raise the notion that vaccination could somehow, potentially, be regarded as a bad thing. It’s obviously not. But the word inequity, in contrast with inequality, implies a degree of injustice or unfairness, whereas inequality is simply a quantitative imbalance. Of course, inequality is also often unfair, but then life isn’t fair and that has been starkly demonstrated by the COVID-19 pandemic.
 
There can be little argument about whether pandemics increase inequity. The worst off in society have suffered disproportionately financially and medically - while the wealth of the already stratospherically rich has gone into orbit - sometimes literally. On the basis that vaccines mitigate the effects of pandemics, you could argue that they therefore mitigate that inequity. In one sense, that is true, but of course that beneficial effect is felt unequally, so with the best will in the world, vaccines do increase inequity to the extent that those with wealth, health and education benefit disproportionately. 
 
For the purposes of vaccines, you can roughly divide the global population into 4 groups; those who do or do not have access to vaccines and those who do or do not (or would or would not) choose to take them. Since the days of Jenner himself there have been anti-vaxxers, suspicious of new science and the powers that back it, but I suspect relatively few base their beliefs on a fear of inequity. Vaccines are only effective if people can be persuaded to have them. While some anti-vaxxers have done their homework and come to different conclusions to the majority, many, but not all, are among the less educated, making them susceptible to those deliberately spreading misinformation, or who have a natural tendency to be mistrustful of any government initiative. Others adopted a rather more paradoxical position. Believing themselves to be fit and healthy, they saw no reason to take the infinitesimal risk of vaccination themselves, while relishing the freedoms they enjoyed as a result of millions of others doing so.
 
Nobody, I would assume, would suggest that vaccination is a root cause of inequity, but does exacerbate existing inequity within and between societies. We, in the UK, are hugely lucky to have the wealth of talent and scientific knowledge exemplified by Professor Hill and his colleagues, coupled with the wherewithal to administer the fruits of their labours to protect the population from a novel and vicious disease. However, this at times has led to a rather unattractive “I’m alright Jack” mentality as we watched with relish as politicians in France and other European nations tied themselves up in knots and stumbled with their messaging while we sailed ahead with our impressive vaccination programme. You might even say that, shamefully, some jingoistically enjoyed pipping our neighbours to the post, ignoring what that meant in terms of needless suffering. 
 
Vaccines during this pandemic, setting aside the small matter of saving millions of lives, have been used as political and economic assets. If Boris Johnson survives in office, it will only be because of the UK’s highly-successful vaccination programme - an undeniable achievement for which even his detractors would grudgingly have to give him a shred of credit. Being an incorrigible cynic, I would say that even the calls from the WHO for the rich countries to share their spoils with the developing world are not purely altruistic. While nobody wants to see people dying, the developing world is a key part of the global supply chain which makes us self-interested. 
 
Then there are those demanding shareholders. While it is clearly unrealistic to have suggested that the key players behind the vaccines would make them available to developing countries either before or concurrently with their host nations, there is certainly inequity in how different companies have behaved in terms of pricing. Not mentioning any names of course, some appear to be capitalising more than others. While all vaccine producers are cutting prices for sales to countries which can’t afford them, it is interesting that in 2022, one key producer in particular is forecast to focus its sales almost entirely on high-income countries (presumably on full margin) while, for example, Oxford / Astra Zeneca’s sales are expected to be spread across the global socio-economic spectrum.
 
Therefore, I would argue that, while vaccines do not necessarily cause inequity, they do increase it. Having priority domestic access to any value-added and ubiquitously-needed resource will have that effect. Look at the current energy crisis. The UK being a world-beater in medical science gives us a natural advantage when it comes to creating new vaccines. Of course, it is not the vaccines themselves that increase inequity - it is the financial and political power they represent. We should all be proud, however, that Oxford are setting an example and leading the way among vaccine producers in keeping that inequity to a minimum. 
 
Against - Jack Mitchell - Barrister at Old Square Chambers
 
Inequity is indeed a lack of fairness and justice. One of the concepts was that mRNA was too soon. Distribution is not equitable, but science is also not fair, so does that support or oppose the position as to whether vaccinations in themselves are a proponent of inequity? They are a collaboration between public and private. Why aren’t we putting vaccines into Coca Cola - the most widely distributed soft drink worldwide. The only two countries in the world where it is not number one are France (Orangina) and Scotland (Irn Bru). Darlington in five months were able to create what was necessary in a pandemic, not just for this country but beyond. The concept of thermoaccess is also key. If we want to think about inequity, vaccines are not inequitable - they have merely held up a mirror to our society which is full of inequity. The fact that we can now see that better might help us to reduce it. Context was another theme as to why the motion should be opposed. Thinking of Cassandra, what does the future hold? The issue of thermostability is being addressed, which could mean vaccines could be stored at room temperature for a month. Could the mirror of inequity be about to shatter? To quote Professor Sir Adrian himself, “Vaccines don’t increase inequity”. You are therefore invited to oppose the motion.
 
The room voted overwhelmingly to oppose the motion (to the chagrin of your editor).
 
The evening ended with a fulsome vote of thanks from Lord Wei - Social Entrepreneur and member of the Advisory Board of Future Planet Capital.
 
Conclusion:
 
It must surely be rare for so many scientific luminaries to address outsiders in private session. All those present were the beneficiaries of the real inside track on what is going on in the world of vaccines. We were in the presence of the people who actually did it - who changed the world. Without their skill and dedication, along with that of their colleagues, we could all well still be cowering in mandated isolation. Yet more extraordinarily, millions of people around the world who today are walking around alive and well could be, well, dead. Then there is the countless number of people who will benefit from vaccines yet to be developed. The internet and mobile phones were game-changers (I was going to say killer apps but that doesn’t really work here), but vaccines are the new “saviour app”. Of course, developing vaccines costs money - lots of it - but this is surely an investment in the future of our species. 
 
Soon enough, investment managers will have to explain themselves for not having an exposure…
 

 
Facebook
Twitter
Link
Website
YouTube
Copyright © 2022 FPC, All rights reserved.

This information is being communicated by Future Planet Capital (UK) Limited which is an appointed representative of Midven Limited, which is authorised and regulated by the Financial Conduct Authority. This email message and any files transmitted with it are intended solely for the addressee(s) and are considered privileged and confidential. If you have received this email in error please (i) delete it and all copies of it from your system and (ii) destroy any hard copies of it. You should not divulge, copy, forward, or use the contents, attachments, or information in any way. Any unauthorized use or disclosure may be unlawful. Future Planet Capital gives no warranty as to the accuracy or completeness of email messages and accepts no responsibility for changes made after dispatch.


Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

 

Future Thinking: Blue Ocean Economy

*|MC:SUBJECT|*
March 2022    |    View this email in your browser
Blue Ocean Economy 

This week marks the 4th Monaco Ocean Week, and the 12th meeting of the Monaco Blue Initiative which FPC is attending. The event brings together stakeholders in the marine sector in a week of debate on ocean conservation issues.

There can be no doubt how important debate, analysis and awareness-raising is to better understand the challenges related to the ocean. 

Our oceans make up around two-thirds of our planet, and provide half the oxygen we breathe. According to the World Economic Forum, they have the potential to absorb around a third of global CO2 emissions, making them critical in the fight against climate breakdown.

Overfishing, climate change, pollution, habitat destruction, invasive species, and other forms of human exploitation have put our ocean at risk. No area has been left untouched and there is growing mainstream and investor awareness of the oceans and the role we can all play in ocean health. 

To ensure a sustainable future, it is vital that we reverse this and protect and preserve healthy marine ecosystems. As Andy Muir, Blue Ocean Lead at FPC
says, ''There is some truly inspiring innovation taking place in this space. We want to turn the spotlight on the most impactful solutions and technologies aiming at protecting the global ocean and highlight the essential role of entrepreneurship, innovation and investment to develop a sustainable blue economy.'

We're pleased to use this newsletter to highlight a number of key trends in this area. As well as sources to learn more about the vital importance of a Blue Ocean.
Attenborough's message for World Oceans Day

A powerful video message from Sir David Attenborough was presented to 90 Heads of State at the opening of the United Nations Ocean Conference.
 

Blue Ocean Innovation 2022

The United Nations’ Sustainable Development Goal 14 is to “conserve and sustainably use the oceans, seas and marine resources.”

To achieve this, it is important to support the blue economy encouraging sustainable start-up companies, innovators and innovations that can scale to solve the ocean’s grand challenges.

 
1. Plant-based fish and seafood products: Plant-based innovation is one of the biggest and most exciting growth areas in the food industry today, and while meat substitutes are the fastest growing sub-category in this market (an increase of 152 percent in 2019), fish and shellfish alternatives are now poised for dynamic growth. Investment in alternative fish and seafood startups has been brisk, with new companies and products starting to expand the market.
2. Reversing the plastics crisis: Plastics are useful. They're used to help make lifesaving medical supplies, lightweight, fuel-efficient car parts, and insulation for our homes. But nearly half of all plastic produced goes towards single-use items such as bags, straws, utensils and takeout containers. There's a number of companies trying to develop cost-efficient and eco-friendly substitutes, from mushroom packaging to advanced fibers and plastic-free online shopping. 
3. Ocean-based renewable energies: Rapid transformation of our energy systems is required if we are to achieve the goals of the Paris Agreement and limit the global average temperature rise. In addition to expanding land-based renewable energy, the ocean offers significant potential for supporting this transition. However, new technologies must be implemented in a sustainable way in order
to avoid unintended consequences that could undermine other aspects of ocean health.
Roslin Technologies
- the future of meat for ourselves and our pets!

We recently co-hosted a breakfast with Roslin Technologies, which brought together leading voices from investment, policy, business, academia, and civil society.

Our aim was to share perspectives and learn about the opportunities and challenges in taking cultivated meat from the laboratory to the supermarket shelf, whilst explaining how cultivated meat can help solve global food security by providing affordable, nutritious food to billions with a significantly reduced carbon footprint.

Cultivated meat uses significantly less land, water and energy than conventional meats. The Good Food Institute study has shown fully adopting lab-grown meats could lead to a 92% reduction in meat emissions, at a similar production cost.

Technology, policy, investment, business models, and public acceptance will influence the pace of adoption. And building on its historic strengths in biotechnology, life sciences, and innovation, the UK could prove to be one of the leading countries in developing and capturing the value from this growing market.

Roslin Technologies is an advanced biotechnology spin-out from the University of Edinburgh’s world-leading Roslin Institute, which has created self-renewing stem cells being used by many of the leading players in the cultivated meat production industry. The company was featured in The Times yesterday and we'd be delighted to share further news with you.

Please get in touch to find out more. 
Challenge Investing

Within our universe, we have a significant number of companies that are helping to profitably address this significant and timely global challenge. If you’d like to invest in some of the most promising growth companies based on top research then please don't hesitate to get in touch.
 
Want to know more?
Contact Ed Phillips or Abi Wye at Future Planet Capital. 

 
Website
Twitter
Facebook
LinkedIn
Email
Instagram
YouTube
This monthly digest is brought to you by Future Planet Capital

This information is being communicated by Future Planet Capital (UK) Limited which is an appointed representative of Midven Limited, which is authorised and regulated by the Financial Conduct Authority.This email message and any files transmitted with it are intended solely for the addressee(s) and are considered privileged and confidential. If you have received this email in error please (i) delete it and all copies of it from your system and (ii) destroy any hard copies of it. You should not divulge, copy, forward, or use the contents, attachments, or information in any way. Any unauthorized use or disclosure may be unlawful. Future Planet Capital gives no warranty as to the accuracy or completeness of email messages and accepts no responsibility for changes made after dispatch.


Copyright © 2022 Future Planet Capital, All rights reserved.

Want to change how you receive these emails?
You can
update your preferences or unsubscribe from this list.
 

Future Thinking: Vaccines, Infectious Diseases & Healthcare Innovation

*|MC:SUBJECT|*
February 2022    |    View this email in your browser
Vaccines, Infectious Diseases & Healthcare Innovation:
Saving Lives and Livelihoods

It's now been over two years since the start of the coronavirus pandemic which has disrupted lives across all countries and communities. Over 400 million covid cases have been reported worldwide and well over 100 countries worldwide have instituted either full or partial lockdowns, affecting billions of people and businesses. 

But in the midst of this unprecedented global crisis, there has been a saviour that has reduced fatalities and helped us to reopen our economies - vaccinations. From the start of the pandemic, the global innovation community mobilised quickly to initiate the develop a vaccine for COVID-19. Hundreds of individuals and institutions—in academia, biotechnology, government, and pharmaceuticals—embarked on one of the most consequential scientific endeavours in living memory. FPC was in the thick of the race from the very beginning investing in Vaccitech, the company behind the Oxford/AstraZeneca vaccine.  

Now, 10.4 billion doses of covid vaccinations have been administered worldwide with over 50% of the global population fully vaccinated against the disease. Funding has poured in from governments, multilateral agencies, not-for-profit institutions, and the private sector. Although it certainly hasn't been plain sailing, regulators have shown unprecedented speed in working with innovators.

The vaccine race has shown the importance of healthcare innovation and how it can be vital to keeping our economies moving forward. 

There are also significant lessons to be learnt. As we look towards a post-covid era - with our healthcare systems facing ever-growing demands and burgeoning waiting lists - it is important that we build on recent developments and innovations. And perhaps help protect ourselves from the pandemics of the future.

This newsletter highlights a number of interesting sources in this area and sets out the trends to watch out for in healthcare innovation for 2022.


 
BBC Horizon Special: The Vaccine 

The extraordinary inside story of the biggest scientific challenge of our age – following a small band of vaccine scientists around the world who took on Covid-19 and ultimately delivered the weapon to beat it. 
 

Three Healthcare Trends for 2022

We have all seen and experienced the sweeping digital transformations made in healthcare over the past two years. It has been the perfect convergence of the capabilities of technology being available at the right time and the environmental constraints of Covid-19 forcing the innovation to happen. Over the next 12 months, important changes in healthcare will continue and, while the pace of innovation may slow slightly, technologies such as AI, wearables and new telehealth systems will continue to play a significant role in helping us get and stay healthy.

Next generation vaccines will also play an increasingly important role as we prepare ourselves for the healthcare challenges of the future. 

 
1. Equity In Care: Around the world the pandemic has shone a spotlight on the inequities. We see the rate of vaccination correlates with the GDP of nations, and there’s widespread recognition that more must be done. This fourth industrial revolution spurred by technology could be the most inclusive, if we structure our systems with inclusivity and equity in mind. Next gen vaccines could be an important tool in this fight for greater equity.
2. Personalised medicine and genomics: Traditionally, medicines and treatments have been created on a "one-size-fits-all" basis, with trials designed to optimise drugs for efficacy with the highest number of patients with the lowest number of adverse side effects. Modern technology, including genomics, AI, and digital twins, allows a far more personalised approach to be taken, resulting in treatments that can be tailored right down to the individual level.
3. Remote healthcare and telemedicine: During the first months of the pandemic, the percentage of healthcare consultations that were carried out remotely shot up from 0.1% to 43.5%. Analysts at Deloitte say that most of us are happy with this and will continue to use virtual visits. Telemedicine has the potential to improve access to healthcare in a world where half the population does not have access to essential services (according to the WHO). 
FT Opinion: Three ways to ensure health tech innovation benefits all

Read Susan Etlinger's recent article in the Financial Times about why we should focuss innovation on those who face the toughest barriers - developing healthcare technology with historically marginalised people rather than for them.
Challenge Investing

Within our universe, we have a significant number of companies that are helping to profitably address this significant and timely global challenge. If you’d like to invest in some of the most promising growth companies based on top research then please don't hesitate to get in touch.
 
Want to know more?
Contact Ed Phillips or Abi Wye at Future Planet Capital. 

 
Website
Twitter
Facebook
LinkedIn
Email
Instagram
YouTube
This monthly digest is brought to you by Future Planet Capital

This information is being communicated by Future Planet Capital (UK) Limited which is an appointed representative of Midven Limited, which is authorised and regulated by the Financial Conduct Authority.This email message and any files transmitted with it are intended solely for the addressee(s) and are considered privileged and confidential. If you have received this email in error please (i) delete it and all copies of it from your system and (ii) destroy any hard copies of it. You should not divulge, copy, forward, or use the contents, attachments, or information in any way. Any unauthorized use or disclosure may be unlawful. Future Planet Capital gives no warranty as to the accuracy or completeness of email messages and accepts no responsibility for changes made after dispatch.


Copyright © 2022 Future Planet Capital, All rights reserved.

Want to change how you receive these emails?
You can
update your preferences or unsubscribe from this list.
 

Future Thinking: EdTech

*|MC:SUBJECT|*
January 2022    |    Did someone forward you this email? Subscribe Here
EdTech:
Trends for 2022
Educational technology, or ‘edtech’, is the use of hardware and software products to facilitate learning. The edtech sector has grown rapidly in recent years; global venture capital investments in edtech crossed US$20bn in 2021, now 40x larger than it was a little over a decade ago (HolonIQ). US$87bn is expected to be invested in the sector over the coming decade (Holon IQ), with China and India anticipated to have the fastest growth.

Edtech promises reduced costs, higher quality pedagogy, and impactful outcomes beyond the traditional classroom setting. The sector now sees a diversity of segments, ranging from K-12, post-secondary, digital courseware, employment training, learning analytics, and even blockchain applications. Owl Ventures, the largest edtech VC in the world and a partner of Future Planet, highlight in their 2021 Education Outcomes Report the most exciting trends and portfolio companies addressing this important global challenge. 


There can be little doubt that edtech has emerged as a growth powerhouse, supporting the economy through investments and new jobs. We see the future only going one way - with the current edtech landscape developing further with new products, focusing on providing a more customised and personalised learning experience for users. 

Below we outline three key focus areas to keep an eye on for the year ahead.
 
1. Immersive Learning
Extended reality (XR) is an umbrella term for a combination of technology with the real environment, and notably includes augmented reality (AR) and virtual reality (VR). The pedagogical benefits to consumers are obvious; an immersion in their learning that connects their personal perspective to their education. Interest and potential in XR products have risen dramatically. The market for AR in education will be over US$5bn by 2023, and VR head-mounted displays alone in education will grow to nearly US$700mn by 2025 (ABI Research). With costs for VR products lower than ever before and mobile AR/VR applications already inexpensive or completely free, the possibility for immersive learning is already here. The applications of AR and VR in education are wide-ranging and open a world of possibilities. 
 
2. E-Learning
Given COVID, this move to online learning should not come as a surprise. However, more than a temporary trend, e-learning is here to stay. Given its benefits of flexibility, affordability, and accessibility, e-learning represents a new, modern approach to how we conduct education. The global e-learning market was worth US$250bn in 2020, and is set to exceed US$7tn by 2027 (Global Market Insights), with segments as diverse as video conferencing applications, online simulator products, and online courses. The latter segment is particularly popular, with massively open online courses (MOOCs) being offered by companies like Coursera and Udemy (a 500startups company) in collaboration with world-leading universities.
 
3. Rise of AI
The global market for AI in education was worth over US$1bn in 2020, and is expected to be worth US$22bn by 2028 (Verified Market Research). AI, in tandem with machine learning (ML), enables adaptive learning; meaning teaching modulated to fit students’ needs in real time. This allows for an efficient and personalisable learning experience, with applications to voice assistants, assessment tools, adaptive interfaces and automated teaching services. Established edtech companies have already recognise the power of AI in education and with the continual rise of e-learning in the future, expect to see AI and ML being increasingly integrated into edtech offerings.
Challenge Investing

Within our universe, we have a significant number of companies that are helping to profitably address vitally important global challenges. If you’d like to advise, invest in or support some of the most promising growth companies based on top research then please don't hesitate to get in touch.
Want to know more?
Contact Ed Phillips or Abi Wye at Future Planet Capital. 

 
Website
Twitter
Facebook
LinkedIn
Instagram
YouTube
Email

This monthly digest is brought to you by Future Planet Capital

This information is being communicated by Future Planet Capital (UK) Limited which is an appointed representative of Midven Limited, which is authorised and regulated by the Financial Conduct Authority.This email message and any files transmitted with it are intended solely for the addressee(s) and are considered privileged and confidential. If you have received this email in error please (i) delete it and all copies of it from your system and (ii) destroy any hard copies of it. You should not divulge, copy, forward, or use the contents, attachments, or information in any way. Any unauthorized use or disclosure may be unlawful. Future Planet Capital gives no warranty as to the accuracy or completeness of email messages and accepts no responsibility for changes made after dispatch.
 
Copyright © 2022 Future Planet Capital, All rights reserved.

Want to change how you receive these emails?
You can
update your preferences or unsubscribe from this list.
 

The Wei Forward: Impact Report

Why impactful investing is the way forward in 2022

by Lord Nat Wei of Shoreditch, Advisory Board Memeber Future Planet Capital

With the unprecedented levels of change inflicted by the COVID-19 pandemic, rapidly shifting geopolitics, and the race to get to net zero since COP26, it is clear the world needs to accelerate its innovation and development processes to protect our planet and the human race. Businesses, governments, and NGOs must work together urgently to find solutions.

But there is a vital tool at our disposal that is grossly underused: impactful investing. Innovation and new, disruptive technologies are critical in making progress towards the Sustainable Development Goals (SDGs) and the climate-specific pledges made at COP26, to decentralising our healthcare system to immunise it from future lockdowns, and to make our supply chains and energy systems more resilient to combat inflation and rising living costs. Yes, there has been admirable progress in many areas, but the fact remains that today the technologies simply do not exist to achieve Net Zero in the developed world cost-effectively, or to combat the next pandemic more effectively than we have done so far. World leaders have talked the talk; now researchers, engineers, business leaders and investors need to walk the walk for them. This is where impactful investing comes in.

Experience tells us the greatest technological progress is made by start-ups and scale up businesses, with solutions that government, corporates, and society can get behind when they are needed. Backing innovative solutions to solve pressing issues requires joint action. There must be a concerted effort made by all these stakeholders to unlock impactful investment. Imagine what would happen if we found and unleashed more Kate Binghams (herself a venture capitalist) and the innovative companies they could help us direct resources to not just to procure new vaccines but to revamp the NHS? Or find ways to heat our homes and power our grid more efficiently. Or ultimately help keep taxes low by helping us transition as a country to be more resilient and agile in the face of climate change and future supply and other shocks?

Government should look to play a larger role as a procurer of innovation and encourage impactful venture investing with green and impactful-oriented tax breaks. Pensions industry regulators should take a more balanced risk approach and favour impactful investing so there is a decent world for the pensioners of the future to live in while also boosting the long-term value of their pensions. To not do so, given the societal and planetary risks we face, is a risk itself; one that the regulatory system should be accountable for, alongside protecting the immediate financial returns and assets of members.

Finally, it is essential that society has a more active role in holding legislators, regulators and board members to account, using tools such as the Companies Act 2006, Section 172. All too often we have seen company directors knowingly ignore their duty to help society and the environment, in favour of ill-gotten benefits for a few, just as big tobacco did decades ago. This cannot continue, and customers know it.

The investment community itself has a major role to play. It must look at how best to scale the field of impact, transforming it from a niche, historically less focused on profit asset class, to a

mainstream practice centred around high impact, high profitability, and large global funds. This may require adapting and simplifying approaches; as Tom Beagent, a leading expert in impact at PwC, rightly says: “All investments make impact, good or bad – impact investing is about creating more positive impact.” This transition may also require a reconciliation in academic research between what works practically on the ground for investment professionals and entrepreneurs, and what drives them both financially and socially. This is needed to align incentives amongst the investors, and the investors and the market. It is not a zero-sum game.

But we must be positive and not despair about the challenges ahead. We have the talent, skills and resources, and there are already key players leading the charge such as Future Planet Capital (FPC), who have exemplified a pragmatic approach to creating solutions to huge global challenges, marrying profit and purpose. Whilst the marked growth of impactful and Environmental, Social and Governance (ESG) considerations among investors is encouraging and actors, like FPC, look to generate positive change, we, as an investing community, should remain mindful not to overpromise. It is essential that progress is meaningful and long-term rather than superficial or a ‘quick fix.’

Much of the responsibility for pushing impactful investing rests with VC investors and founders. However, everyone must act responsibly and be accountable. The potential for policymakers, regulators, LPs, pension funds and consumers to play an influential role in bringing impact to mainstream adoption must be recognised and harnessed. A culture change will be needed in Whitehall, in the City, and in the wider country, and there will be bumps along the way as we seek to procure differently, invest more purposefully, and demand those who govern us to be more solutions-focused. We are just at the beginning and the road ahead may seem long, but we must start having joined-up conversations about how we may all endeavour to deliver this change, with impactful investing providing a potential very practical way forward into 2022 and beyond after major shifts caused by Brexit, Covid, and COP26.

By Lord Wei, Author of the Wei Foreward report published by Future Planet Capital.

Fusion Energy- The Future of the World's Energy

The UK Innovation & Science Seed Fund (UKI2S) first invested in Tokamak Energy over a decade ago when fusion energy companies were few and far between. We knew it would be a long haul, but we always believed that momentum would build. So we are delighted to see that there are now multiple companies who between them have raised well over $4 billion, with the last few weeks seeing a flurry of announcements from Helion, Commonwealth Fusion Systems and General Fusion with some very large sums being bandied around. These financings are very welcome news and reinforce the growing perception that fusion energy has moved from the realm of science fiction to that of an engineering problem. In other words there is confidence that time and money and application will deliver a viable source of carbon free energy at some point in the not too distant future.

Of course this is not going to be tomorrow but sometime in the next decade. And the engineering needed to get there is non-trivial. From power electronics and AI systems capable of controlling unstable plasmas through to radiation resistant materials for the inner walls of the reactors, there remains a huge amount of work to be done. Much of it will need to be done in collaboration with government labs and academia, but there will also be massive opportunities for the private sector to be innovative suppliers to the fusion companies. This has the potential to create technology leaders in fields outside fusion, perhaps before fusion itself is realised.

TAE Technologies have already spun out a company TAE Life Sciences, using TAE’s particle accelerator technology to create a compact neutron source that can be used to target boron-doped tumours more accurately. Elsewhere, one of the most interesting enabling technologies is the magnets that confine the plasma and the materials that they use. High temperature superconducting (HTS) materials first emerged in the lab about 40 years ago but have been a wonder material struggling to find a sufficiently attractive application. But the compact tokamak devices being developed by Tokamak Energy and Commonwealth Fusion Systems use HTS magnets and the know how being applied to magnets for fusion is already sparking thoughts of other applications ranging from space propulsion systems to portable MRI scanners that could save lives at the roadside.

At UKI2S we have already invested in two start-ups that are a by product of the race to fusion, in the form of Luffy AI and Qdot Technology. Qdot’s expertise lies in thermal management and they are looking to bring the skills used to design the exhaust system for fusion reactors to bear on current problems such as the charging cycle for EV batteries. Whilst Luffy, whose founders emerged from UKAEA’s Culham site, are developing a neural network that could be transformative in improving robotic and industrial controls.

The word “moonshot” is over-used and is often taken to mean something that is binary in outcome. Win big or lose all your money, in other words. Fusion energy is definitely a big win, no doubt about that. But it is also a moonshot in the sense of the Apollo Space programme, which gave us core aspects of our daily lives in the form of the silicon chip, fly-by-wire and freeze-dried foods, all of which were either direct creations of the programme or massively accelerated by it. Fusion technologies could do the same and give us new capabilities few of us will even have on our horizons. Watch this space.

By Mark White, Investment Director at UK Innovation & Science Seed Fund (Future Planet Group)

The Democratisation of Venture - Is it Time for the Industry to Grow Up?

Future Planet Capital was founded with the vision of connecting the world’s biggest investors to the brightest minds to address global challenges profitably. In our early years this meant targeting sovereign investors and governments, pension plans, corporates and, in partnership with Barclays Private Bank, ultra-high net worth individuals. But there is one “biggest investor” group that until now we have not and covered and that is the “Crowd”. In this blog, I explore the importance of democratising access to venture and what that means in terms of economic efficiency and financial inclusion. 

How Big is the Crowd? 

According to Bloomberg and the Securities and Exchange Commission, throughout much of 2021 the share of total equity volume traded by individual investors in America has been well above 20%.   In a market worth well over $30trillion, that makes individual or retail investors very big indeed. In the US, the poster child for retail investors is Robin Hood who have over 22m clients or 8.5% of the adult population. In Britain, CrowdCube and Seedrs have financed some of the country’s biggest success stories most notably Revolut, the next-generation bank whose stock market value now exceeds that of all but one of Britain’s traditional banks. 

In short, the Crowd is big, very big. 

Why Democratise Venture? 

From a Future Planet Capital perspective, with our eyes on the world’s biggest investors then it makes absolute sense to find channels to market to this Crowd, to find ways to democratise venture. 

For the industry as a whole, it also makes sense. As The Economist’s lead article this week makes clear, 7 of the world’s top 10 companies were venture capital backed. This is great but the traditional investor base for venture capital is geographically centred on Silicon Valley and driven largely by ultra-high net worth individuals and endowments. In more recent years, Chinese-led corporations, such as Alibaba or Tencent, have overtaken Californian investors. This makes the industry highly dependent on a small number of names and their enthusiasm will be driven by fashion, feast and famine depending not only on their own financial well-being but political and tax considerations too. 

For individuals, the fact that so much of the world’s increase in wealth has come from private markets has further accelerated income and wealth equality.   

It’s not good for the industry to be dependent on a handful of billionaires and their companies and even less so for the ordinary individual who has no access to this deal-flow. For both diversified, more stable economic growth and for fairness, it would make sense for venture to be democratised.     

Democratisation in Practice 

From 2022, Future Planet Capital will be making 10% of its deal flow available to individuals via crowdfunding platforms. For sophisticated individuals this can be on a deal-by-deal basis. For purely retail investors with limited wealth it will be via long-term diversified investment products. For the first time, individuals will have the same privileged access to impact and innovation companies emerging from the world’s top universities and research centres. Our launching partner, Seedrs, with whom we’ve raised our own Series A, has just been acquired by Republic, the US based private investment platform. With these partners and others, we expect over time to provide fair access to top deals. 

Over the long-term, however, our ambition is to link venture capital products to long-term individual savings plans. For those saving for a pension with a multi-decade time-horizon and no need for liquidity, diversified-venture portfolio’s are surely an effective way to fund individuals’ long-term liabilities.   

Groups such as MakeMyMoney matter are also advocating for individuals to take control of the ethical implications of their investments and the impact of their financial commitments.  Indeed for many this is the biggest way that they can make a difference to the challenges of climate change, education, health, security and sustainable developments. 

So, perhaps paradoxically, for venture capitalists, for the industry as a whole, for individuals and for the planet, democratisation of venture is a key stage in the institutionalism and scaling-up of an important asset class.   

By Douglas Hansen-Luke, Executive Chairman 

Venture Capital Battles in the Fight Against Climate Change

Future Planet Capital were honoured to have been invited to #COP26 by His Royal Highness, Prince Charles, to support his work with #terracarta and the Sustainable Markets Initiative. There we showcased seven companies that were able to make a clear impact in facing down the challenge of climate change.

Where were the venture capitalists?

Sifted recently wrote that apart from ourselves and a small number of others the #venturecapital industry failed to make an appearance at COP26 and lamented that this key driver of innovation was noticeably absent. Aside from ourselves, General Atlantic were present and they announced a $4bn late-stage venture #climatechange fund. Few of Europe's top 40 sustainable venture groups made it to COP26. Does this reflect an industry failing?

What is the venture industry doing?

I say "No". In fact venture is already making considerable investments in climate change and is further aware of the wall of funding destined to follow from asset managers, corporates and governments. The industry is on the right track and as detailed in the forthcoming Lord Nat Wei's report "The Wei Forward" there are many practical paths for impactful investment to follow, be measured and be recognised.

In our own portfolio and pipeline we number nuclear fusion, sustainable fashion, circular supply chains, smart materials, smart cities and agritech companies as all capable of making an impact through improved energy usage, reduced emissions, circularity, fixing food and protecting the environment. There is a shortage of dealflow relative to demand but it cannot be said that venture is ignoring climate change or failing to make a difference. Instead it is performing a valuable purpose in ensuring that only the best, most practical, most impactful, companies get the majority of funding.

The Business and Sustainable Development Commission estimates that $45 trillion needs to be invested in addressing climate change by 2030. This money can be sourced from the $130 trillion that the Glasgow Finance Alliance for Net Zero (GFANZ) has pledged by 2050 but it needs to find routes for deployment.

The solution is in our hands...

And it is here that Venture can be helped by all those governments, corporates and indeed activists who attended COP. Through a series of nudges more funding can be released and rushed to innovative technologies targeted to beat climate change.

One of the most effective actions available to governments would be to free occupational pensions to invest more in venture. In the UK alone over $1 trillion is managed by local government pensions but their allocation to venture is minimal. This needs to change but in a highly conservative industry this needs encouragement from government. For corporates, similar nudges are required. At all annual general meetings shareholders who talk of engagement must insist on an #ESG policy and one which explicitly targets #netzero. A great example of leadership comes from Arcelik Global and its CEO, Hakan Bulgurlu. Awarded a Terra Carta award for their vision this top 3 manufacturer of air-conditioners and white goods has pledged to be fully carbon neutral within a decade.

And, in the final analysis, it is activists and individual consumers who will make the biggest difference. As voters, activists at shareholder meetings, as employees or through purchasing decisions, individuals in their millions can influence the largest governments and corporations.

So, "Yes", venture is making a difference to investing in impact and innovation but, individuals, all of us, are able to influence, lead and accelerate everything the industry does.

By Douglas Hansen-Luke, Executive Chairman

Future Thinking: Sustainable Growth

*|MC:SUBJECT|*
October 2021    |    Did someone forward you this email? Subscribe Here
Sustainable Growth:
for now and the future
At Future Planet, we are an impact-led, global venture capital firm built to invest in growth companies from the world's top universities. We provide venture and growth funding to entrepreneurs and businesses, profitably solving the world's greatest challenges in Climate Change, Education, Health, Sustainable Growth & Security.

From our focus areas, the challenge we get asked about most is Sustainable Growth. People are often confused by the term. We all know that it is a good thing - but what does it really mean? We wanted to re-explore this topic that we last picked up at the end of May.

It is clear that everything is continually changing and growing. It is also increasingly evident that many of the challenges facing humankind, such as climate change, water scarcity, inequality, and hunger, can only be resolved at a global level by promoting growth sustainably.

As a part of the sustainable development roadmap, in 2015, the United Nations approved the 2030 Agenda, which contains the Sustainable Development Goals (SDGs). They are a call to action to protect the planet and guarantee the global well-being of people. These common goals require the active involvement of individuals, businesses, administrations and countries around the world - and they are what we at FPC have built our thesis around. 

Sustainable Growth is central to SDGs - it is a commitment to social progress, environmental balance and economic growth.

Last year's Sustainable Development Report noted that five years since the adoption of the Sustainable Development Goals, progress had been made in some areas, such as improving maternal and child health, expanding access to electricity and increasing women’s representation in government. Yet even these advances were offset elsewhere by growing food insecurity, deterioration of the natural environment, and persistent and pervasive inequalities.

It is evident that we need to refocus and ensure that we are supporting sustainable growth that meets the present's needs without compromising the ability of future generations to meet their own needs.

Progress toward any worthy objective is enhanced when people work together to create solutions. We have this opportunity - it's ours to grasp together!
The United Nations Sustainable Development Goals (SDGs), are a universal call to action to end poverty, protect the planet and ensure that all people enjoy peace and prosperity.
1. Economic Growth
Sustainable economic growth means a rate of growth which can be maintained without creating other significant economic problems, especially for future generations. There is clearly a trade-off between rapid economic growth today, and growth in the future. Rapid growth today may exhaust resources and create challenges for future generations. At the same time, sustained and inclusive economic growth is absolutely vital and can drive progress, create decent jobs for all and improve living standards. 
 
2. Environmental Balance
The global economy faces significant environmental challenges, from averting dangerous climate change to halting biodiversity loss and protecting our ecosystems. Natural resources are ultimately vital for securing economic growth and development, not just today but for future generations - and we are pleased to see a number of exciting companies leading the way and demonstrating that it is possible to achieve economic growth whilst also tackling these challenges.
 
3. Social Progress
The human condition is not reflected simply by GDP statistics. Social progress can be overlooked but is incredibly important. Social sustainability is a process for creating sustainable successful places that promote wellbeing, by understanding what people need from the places they live and work. Social sustainability combines design of the physical realm with design of the social world – infrastructure to support social and cultural life, social amenities, systems for citizen engagement, and space for people and places to evolve. It is the ability to develop processes and structures which not only meet the needs of now, but also support the ability of future generations to maintain a healthy community.
Architect, and FPC Advisory Board Chairman, Norman Foster discusses his own work to show how computers can help architects design buildings that are green, beautiful and "basically pollution-free." From the 2007 DLD Conference, Munich; www.dld-conference.com
Challenge Investing

Within our universe, we have a significant number of companies that are helping to profitably address this significant and vitally important global challenge. If you’d like to invest in some of the most promising growth companies based on top research then please don't hesitate to get in touch.
Want to know more?
Contact Ed Phillips or Abi Wye at Future Planet Capital. 

 
Website
Twitter
Facebook
LinkedIn
Instagram
YouTube
Email

This monthly digest is brought to you by Future Planet Capital

This information is being communicated by Future Planet Capital (UK) Limited which is an appointed representative of Midven Limited, which is authorised and regulated by the Financial Conduct Authority.This email message and any files transmitted with it are intended solely for the addressee(s) and are considered privileged and confidential. If you have received this email in error please (i) delete it and all copies of it from your system and (ii) destroy any hard copies of it. You should not divulge, copy, forward, or use the contents, attachments, or information in any way. Any unauthorized use or disclosure may be unlawful. Future Planet Capital gives no warranty as to the accuracy or completeness of email messages and accepts no responsibility for changes made after dispatch.
 
Copyright © 2021 Future Planet Capital, All rights reserved.

Want to change how you receive these emails?
You can
update your preferences or unsubscribe from this list.